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The focus of this dissertation is the characterization of the effects of developmental (in 
utero) aryl hydrocarbon receptor (AHR) disruption in the embryo and its consequences to the adult, 
primarily regarding the role of this receptor in cardiogenesis, cardiac homeostasis, and cardiac 
function. Perturbations in cardiogenesis may result in structural and functional defects broadly 
categorized as congenital heart disease (CHD). With about 2 cases per 1,000 live births, CHDs are 
the most frequent type of congenital disease in newborns, resulting in a major burden with direct 
social and economic impacts in the developed and developing world. Considering that the vast 
majority of CHD cases cannot be directly attributed to specific disease-causing mutations, gene-
gene and gene-environment interactions have emerged as significant contributors in the etiology 
of most non-syndromal forms of CHD. Epidemiological studies have identified links between 
environmental exposures to AHR ligand pollutants and congenital or adult cardiovascular disease. 
In this context, as a mediator of environmental sensing, the AHR has a potential role in the 
pathogenesis of CHD. Ultimately, furthering our understanding of the roles of the AHR in heart 
development in health and disease, and as an etiological nexus for CHD, will contribute to the 
understanding, treatment and prevention of the majority of CHD cases. Chapter One summarizes 
the current body of knowledge regarding CHD, the AHR, heart development, and mitochondria as 
it relates to heart development and function. Chapter Two describes a mouse model of 
environmental in utero AHR disruption, and characterizes the effects to cardiogenesis at key 
developmental windows at the molecular, structural, ultrastructural, and functional levels. Chapter 
Three further investigates the phenotypes produced by in utero AHR disruption to the young and 
adult heart in the pre-established mouse model. Finally, Chapter Four discusses the findings of the 
studies described in prior chapters and outlines the overall conclusions and implications. Overall, 
the results presented throughout this work illustrate and further emphasize that the AHR signaling 
in the developing mammalian heart is central to the regulation of endogenous pathways crucial for 
cardiogenesis, cellular metabolism, and cardiac function, and that the AHR is a potential target of 









My heartfelt gratitude goes to Dr. Alvaro Puga for welcoming me into his lab and 
mentoring me as a graduate student. I sincerely appreciate all the wisdom, guidance, constructive 
discussions, and above all, the bottomless generosity, friendship, and respect dispensed over the 
course of my studies.  
 
I am thankful to all of the members of my dissertation committee for their collegial support, 
criticisms, suggestions, and guidance that collectively provided the basis for this thesis. My thanks 
to Drs. Mary Beth Genter, Ying Xia, Jack Rubinstein, and Brad Bolon for all their help and 
encouragement. 
 
I am also very grateful for Yunxia Fan for the outstanding technical support and 
friendship, and for my classmates, lab partners, and many faculty members of the Department of 
Environmental Health’s Division of Toxicology who have all helped me throughout my studies.  
 
Thank you to my parents, Valdir and Eliana, for providing me with excellent education 
opportunities, values, and emotional skills to succeed in life. Thank you to my wife, Sarah, and 
my daughter, Eva Cecilia, for providing me with unconditional love, happiness, and grounding 
from the challenges of the outside world. I am grateful to all my family members who also provided 
absolute support throughout the many years of higher education.    
 
Finally, I would like to express my sincere gratitude to all the funding agencies and 
mechanisms that enabled my graduate studies by fomenting the work presented herein. This 
research was supported by National Institute of Environmental Health Sciences (NIEHS) 
grants R01 ES06273, R01 ES024744, and R01 ES10807, and by the NIEHS Center for 
Environmental Genetics grant P30 ES06096. In addition, my stipend was supported by NIEHS 




Table of Contents  
Abstract…………………………………………………………………………...………….……ii 
Acknowledgements…………………………………………………………….……...….…...….iv 
List of Figures…………………………………………………………………………..…………7 




An Overview of Congenital Heart Disease, Aryl Hydrocarbon Receptor, Heart Development, 
and Mitochondria Current Literature  
Introduction…………………………………………………………….………………...………13 
Congenital Heart Disease (AHR)………...………………………………….…………...……... 13 






Chapter Two  




Materials and Methods……………………………………….…………………………......……33 
Results………………………………………………………….…………………………...……37 








Chapter Three  
Disruption of Ah Receptor Signaling during Mouse Development Leads to Abnormal 
Cardiac Structure and Function in the Adult 
Abstract……………………………………………………………………………….…….……86 
Introduction………………………………………………………………………………………87 









Discussion, Implications, and Future Directions  
Discussion………………………………..…………….………………………………….……134  






List of Figures 
Chapter 1 
Text Figures 




1 - AHR localization during early heart formation in the mouse………………………..….……58 
2 - Structural changes in the developing myocardium in mice..………………….………...……59 
3 - Effect of developmental AHR disruption on embryonic heart function in mice...………...…60 
4 - AHR signaling networks involved in cardiogenesis and cardiac homeostasis…….......……..61 
5 - AHR regulates NKX2-5 expression in the developing mouse  heart………...………..……..62 
6 - Disruption of AHR signaling perturbs the regulation of molecular networks that control 
mitochondrial function during development…………………………………………….……….63 
7 - Disruption of AHR signaling induces changes in mitochondria abundance and structure…..64 
Supplemental Figures  
S1 - Experimental design and maternal-fetal outcomes of gestational exposure to the prototypical 
AHR ligand (TCDD)……………………………..………………………………………………74 
8 
 
S2 - Annotated representative in utero echocardiography illustrations at E15.5 from Ahr+/+, naïve 
or exposed to AHR ligand (TCDD) in utero, and Ahr-/- mouse embryos……..…………………75 
S3 – High magnification of AHR expression in the developing myocardium at E13.5 from Ahr+/+, 
naïve mice or mice exposed to AHR ligand (TCDD) in utero………………..…………...…….76 
S4 – Ultrathin sections of embryonic mouse hearts collected at E13.5, E15.5, and E18.5 from 
Ahr+/+, naïve or exposed to AHR ligand (TCDD) in utero, and Ahr-/- hearts……….…..………77 
S5 - Experimental design for RNA.seq experiment and analyses and differentially expressed genes 
from naïve Ahr+/+, ligand-exposed Ahr+/+, and Ahr-/- embryonic mouse hearts at different 
developmental time points…………...………………………………….…………….…………78 
S6 - Venn diagrams illustrating the number of commonly differentially-expressed genes in the 
right atrium at E15.5 of Ahr-/- and ligand-exposed Ahr+/+ embryonic mouse hearts, relative to naïve 
Ahr+/+…………………...………………………………………………………………………..79 
S7 - Differentially-expressed Ingenuity® IPA’s networks in naïve Ahr+/+, ligand-exposed Ahr+/+, 
and Ahr-/- embryonic mouse hearts at different developmental time points …………….….…...80 
S8 - Immunohistochemical detection of NKX2-5 in embryonic mouse hearts collected at E13.5, 
E15.5, and E18.5 across subanatomical areas (RA, right atrium; LA, left atrium; RV, right ventricle; 
IVS, interventricular septum; LV, left ventricle) from Ahr-/- and Ahr+/+ either naïve or exposed to 
TCDD in utero……………….……………………………………………………...……………81 
S9 - Ingenuity® IPA Mitochondrial Dysfunction Pathway status at E.15.5 in the right atrium of 
ligand-exposed Ahr+/+ embryo hearts relative to naïve Ahr+/+ embryonic mouse hearts………..82 
9 
 
S10 - Ingenuity® IPA Mitochondrial Dysfunction Pathway status at E.15.5 in the right atrium of 
ligand-exposed Ahr-/- embryo hearts relative to naïve Ahr+/+ embryonic mouse hearts…...…….83 
Chapter 3 
Text Figures 
1 - In utero disruption of AHR signaling affects cardiovascular function in adult mice….……119 
2 - In utero disruption of AHR signaling affects heart structure and transcriptome in adult 
mice……………………………………………………………………………………………..120  
3 - Differentially expressed canonical pathways, toxicological functions, and upstream regulators 
underlie AHR disruption-driven altered structure and function………………………..………121 
4 - In utero disruption of AHR signaling modestly affects calcium-handling signaling…….…122 
5 - Mitochondrial dysfunction and altered oxidative phosphorylation genes in the adult mouse 
heart as a result of in utero disruption of AHR signaling…………………………...……….…123 
6 - Uncoupling proteins are differentially expressed following in utero disruption of AHR 
signaling in naïve Ahr+/+, ligand-exposed Ahr+/+, and Ahr-/- embryonic mouse hearts at different 
developmental time points …...……………………………………………………………...…124 
7 - Disruption of AHR signaling induces changes in mitochondria abundance and structure…125 
Supplemental Figure 
S1 - Experimental design and selected outcomes for gestational exposure to the prototypical AHR 
ligand (TCDD)………………………………………….............................................................130  
10 
 
List of Tables 
Chapter 2 
Supplemental Table 1 - Differentially-expressed genes in the right atrium of naïve Ahr-/- and 
ligand-exposed Ahr+/+ mice at E15.5…………………………………………………………….72  
Supplemental Table 2 - Comparative analysis of differentially-expressed genes in the right atrium 
of naïve Ahr-/- and ligand-exposed Ahr+/+ mice at E15.5 with the previously-published cardiac 
transcriptome of Nkx2-5 mutant mice (Prall et al. 2007)………...………………………..…..…73   
 
Chapter 3 
Supplemental Table 1 - Identity of genes differentially expressed in the mouse embryo at either 
E13.5, E15.5, or E18.5 which persisted in the adult hearts at postnatal day (PND) 300…....…131 
Supplemental Table 2 - Identity, function, targets, and fate of selected cardiovascular signaling 
pathways genes and proteins in cardiac hypertrophy and failure………………………...…….132 
Supplemental Table 3 - Summary of cardiovascular findings related to developmental Ahr 






AHR aryl hydrocarbon receptor 
ATP adenosine-triphosphate 
ARNT ah receptor nuclear translocator 
bHLH-PAS basic-region-helix-loop-helix-PER/ARNT/SIM 
CHD congenital heart disease 
DAPI 4',6-diamidino-2-phenylindole 
DOHaD developmental origins of health and disease 
E embryonic day 
ES 
FADH2 
embryonic stem cells 
reduced flavin adenine dinucleotide 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GD gestation day 
GESC genomics, epigenomics and sequencing core 
H&E hematoxylin and eosin 
IVS interventricular septum 
IPA ingenuity pathway analysis 
LA left atrium 
LV left ventricle 
MRC mitochondrial respiratory chain complexes 
MT masson’s trichrome 
NADH reduced nicotinamide adenine dinucleotide 
NCX sodium-calcium exchanger 
NIEHS national institute of environmental health sciences 
NIH national institutes of health 






PND postnatal day 
RA right atrium 
RV right ventricle 
SERCA sarco/endoplasmic reticulum Ca2+-ATPase 
TAP tandem affinity purification 




toxic equivalence factor 
toxic equivalent 
TF transcription factors 
UCP uncoupling protein 
WACS women’s antioxidant cardiovascular study 
WGA wheat germ agglutinin 




An Overview of Congenital Heart Disease, Aryl Hydrocarbon Receptor, Heart Development, 




1.1. Congenital Heart Disease 
1.1.1. Definition  
Congenital heart defect or disease (CHD) is defined as a “structural abnormality of the 
heart or intrathoracic great vessels that is actually or possibly of functional significance” [1,2], and 
is comprised of a wide set of related structural and functional defects which arise during heart 
development in embryogenesis [3]. CHD structural defects include atrial and ventricular septal 
defects, vascular/valvular stenosis, transposition of vessels, persistency of embryonic structures, 
and single ventricular defects such as hypoplastic left heart syndrome, while functional CHD is 
poorly characterized [4]. CHD can be classified upon the clinical consequence of the defects on 
the physiology of blood circulation into “(1) CHD with increased pulmonary blood flow (septal 
defects without pulmonary obstruction and with left-to-right shunt); (2) CHD with decreased 
pulmonary flow (septal defects with pulmonary obstruction and with right-to-left shunt); (3) CHD 
with obstruction to blood progression and no septal defects (no shunt); (4) CHD so severe as to be 
incompatible with postnatal blood circulation; and (5) CHD silent until adult age” [5]. The first 
four types of CHD according to this classification are more readily diagnosed, which allows for 
therapeutic intervention, which is in contrast to CHD with no clinical manifestation (silent) until 
adult age. Although some types of CHD are amenable to therapy, all non-lethal cases contribute 
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to the ever-increasing prevalence of adults with CHD and the overall burden of adult 
cardiovascular disease in the developing and developed world.  
1.1.2. Etiology 
It is widely accepted that the developmental periods before and immediately after birth are 
critical windows of vulnerability for congenital malformations at large [6]. Still, the precise 
etiological mechanisms at play in most CHD cases are not fully understood [7]. The genetic causes 
of isolated cases of congenital heart disease have been compiled over the past decades to a list of 
over 40 genes largely coding transcription factors (TFs) closely involved in heart development, 
maturation, and function [8].  
Cardiogenesis-related TFs participate in a tightly orchestrated and complex regulatory 
network to promote, stabilize, and reinforce the cardiogenetic program [3,11]. Nonetheless, 
mutations in these TFs are present only in a very low percentage of the cases. In fact, the etiology 
of most forms of CHD is unknown; only ~15% of the cases are ever traced to a known cause [8]. 
Of these, ~10% belong to chromosomal syndromes (i.e., syndromic) such as trisomy 13, trisomy 
18, Down syndrome, Turner syndrome, and DiGeorge syndrome [9]. Single mutations can be 
identified in 0-3% of the sporadic non-syndromic CHD cases [10]. These mutations result in a 
broad spectrum of malformations, including effects to the heart, indicating that the genotype-
phenotype associations are very complex [3].  
CHD has also been clearly associated with specific risk factors which contribute to the 
manifestation of the disease, albeit not necessarily by causing it [12]. Risk factors for CHD include 
maternal phenylketonuria; overall maternal health (age, pregnancy obesity, diabetic status, 
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nutrition); alcohol abuse; rubella infection; febrile illnesses; specific drugs (e.g., thalidomide and 
retinoic acid); and exposure to environmental chemicals [6,8,12,13].  
In summary, since the majority of the cases cannot be directly attributed to specific disease-
causing mutations, gene-gene and gene-environment interactions are predicted to be key 
contributors in the etiology of most non-syndromal forms of CHD [8,9,12]. Ultimately, furthering 
our understanding the etiology of the majority of cases will be crucial to aid in prevention and 
treatment of CHD and its secondary ailments.  
1.1.3. Epidemiology 
With about 2 cases per 1,000 live births, CHDs are the most frequent type of congenital 
malformation in newborns [8]; up to 1.35 million newborns are affected each year [3]. Since CHD 
are, by definition, present at birth, the term “incidence” is replaced by “birth prevalence” as the 
most practical index of the occurrence of new CHD cases in newborns [8]. On the whole, the 
prevalence of CHD (defined as the number of living patients with this disease at a specific period 
of time) is increasing [8,14], with a higher prevalence in Europe relative to North America [8,15]. 
Interestingly, specific defects have a reportedly higher incidence in one gender or the other, for 
instance higher number of females with atrial septal defects and males with transposition of the 
great arteries or aortic coarctation [8].   
CHD remains a major public health challenge notwithstanding dramatic advances in 
diagnosis and therapy. CHD patients are rarely cured and remain susceptible to increased 
cardiovascular morbidity and mortality, largely owing to complications of CHD such as 
endocarditis, arrhythmias, recurrent surgical interventions, pulmonary hypertension, and 
eventually heart failure [6, 8].  
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Seemingly, the emerging epidemiological status of CHD in the developed and developing 
world underscores the contribution of CHD to the burden and social-economic impact of 
cardiovascular disease in the young and adult population. These range from the actual costs related 
to therapy and maintenance of adults survivors of CHD, to the social implications of an increased 
proportion of society living with a chronic debilitating condition such as cardiovascular disease 
(Cardiovascular Diseases in the United Statesi).  
1.1.4. Developmental Origins of Health and Disease  
The theory of Developmental Origins of Health and Disease (DOHaD) proposes that the 
environment encountered during conception, fetal life, infancy, and early adulthood permanently 
changes the body's structure, function and metabolism and shapes the long-term control of tissue 
physiology and homeostasis [16–18]. In other words, a poor start to life is a significant risk factor 
for multiple disorders, particularly non-communicable diseases, which can last until or even begin 
during adulthood.  
It follows that damage during fetal life or infancy resulting from maternal exposure to 
environmental pollutants may be at the heart of many adult-onset disease. In fact, the developing 
heart is exquisitely sensitive to environmental damage, and maternal exposure to environmental 
teratogens was proposed more than 50 years ago to contribute to and potentially explain a large 
proportion of CHD [9], yet little direct evidence has since been developed in the interim that 
directly tested this hypothesis.  
Combined with the evidence that most CHD cases do not have a genetic diagnosis, 
investigating how environmental insults during fetal life result in congenital and adult onset 
cardiac disease is crucial to understanding the etiology of the vast majority of CHD cases. 
Specifically, investigating the potential roles of the AHR in CHD are of great interest due to, 
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among other things, the pervasive nature of the environmental toxicants which are AHR ligands 
and the epidemiological evidence linking these selected toxicants with increased risk of CHD.  
 
1.2. The Aryl hydrocarbon receptor (AHR) 
1.2.1. Historical Perspective 
The description and characterization of the aryl hydrocarbon receptor (AHR) traces back 
to research focused to understand how polycyclic hydrocarbons induce their own metabolism.  The 
original investigations in this field were carried out by Dr. Allan Conney, working in the Millers’ 
laboratory at the University of Wisconsin in the 1950s, and subsequently extended by multiple 
other laboratories [19].  
The receptor was initially studied as the specific binding protein for 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), by using this highly stable and potent ligand activator as a 
bait in a receptor “fishing expedition”. The receptor was first described and named, aryl 
hydrocarbon receptor, in a seminal paper by Okey et. al. 1979 [20], and has since evolved from a 
classical xenobiotic response nexus to a key hub in gene-gene and gene-environment interaction 
networks participating in various endogenous biological processes.   
 
1.2.2. AHR Biology 
1.2.2.1. Xenobiotic and endogenous functions 
As a ligand-activated transcription factor and a member of the basic-region-helix-loop-
helix PER/ARNT/SIM (bHLH-PAS) superfamily, the AHR mediates the ligand-dependent 
activation of xenobiotic metabolism programs, including the CYP1 family of cytochromes P450 
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and several phase II detoxification enzymes [21,22]. A ligand-activated AHR translocates to the 
nucleus, dissociates from its cytosolic chaperones, and heterodimerizes with its ARNT (Ah 
receptor nuclear translocator) partner, which is also a member of the bHLH/PAS family [23]. 
Recruitment of transcription cofactors and associated chromatin remodeling proteins culminates 
in signal initiation of gene transcription following binding of AHR-ARNT complexes to AHR 
response motifs in the promoters of target genes [24]. The basic AHR biology is illustrated in 
Figure 1. In parallel, proteasome-dependent degradation of ligand-activated Ah receptor 
transiently decreases the overall cellular amount of receptor [25,26] and may result in “post-
exposure AHR down-regulation” [19]. Curiously, in contrast to their vertebrate surrogates, AHR 
orthologs in invertebrates like the fruit fly Drosophila melanogaster and the nematode 
Caenorhabditis elegans are not activated by xenobiotic ligands but still control expression of 
homeotic genes involved in development [27–29].  
 
Figure 1. A ligand-activated AHR translocates to the nucleus, dissociates from its cytosolic chaperones 
and heterodimerizes with its ARNT. Recruitment of transcription cofactors and associated chromatin 
remodeling proteins culminates in signal initiation of gene transcription following binding of AHR-ARNT 
complexes to AHR response motifs (xenobiotic responsive elements, XRE) in the promoters of target genes. 
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The physiological pattern of Ahr expression is complex and has been partially delineated 
in a number of previous studies. In mice, the earliest expression report was described in 1-cell 
stage fertilized eggs where detectable levels of Ahr mRNA was demonstrated [30,31] and a high 
activity of the protein (AHR) was identified based on high levels of the AHR target gene Cyp1a1 
[30]. Curiously, no detectable levels of Ahr are present from the 2- through the 8-cell stage, and 
only marginally detectable in the late pre-implantation 32-cells mouse blastocyst [30–32]. 
Conversely, Ahr mRNA can be demonstrated at mouse gestational day 7.5 followed by widespread 
expression in many embryonic tissues in mice [33–36].  
The endogenous AHR signaling network is believed to be mechanistically analogous to its 
induction by xenobiotic ligands [37–39], though to which extent similar biological phenomena 
occur as a consequence of endogenous versus exogenous ligand activation remains to be 
determined. In fact, the endogenous AHR functions are largely unknown at present. Further, the 
potential interplay between endogenous and exogenous roles of the receptor, which may result in 
misappropriation of the network toward one role or the other, are also unclear [40]. Untimely 
activation of the AHR by exogenous ligands during mouse development also appears to 
recapitulate some of the phenotypes observed in the constitutive ablation of the endogenous protein 
[41]. 
1.2.2.2. AHR ligands 
Exogenous AHR ligands include a wide variety of environmental toxicants (e.g., dioxins, 
furans, and polychlorinated biphenyls); bacterial metabolites; or naturally occurring ligands such 
as dietary flavonoids, indoles, and glucosinolates, abundantly found in plants [42]. TCDD is the 
most toxic and potent dioxin, with four chlorine atoms substituted at positions 2, 3, 7, and 8 [43]. 
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TCDD is an environmentally persistent carcinogen [44]. Its environmental stability is largely due 
to high thermal stability (with a melting point at 295 °C and decomposition points at 500 °C); high 
kinetic stability (i.e., inert); resistance to metabolism-dependent degradation; and high lipid 
solubility (lipophilic). Its high affinity for adipose tissue makes it biopersistent in the food chain 
[45].  
TCDD is generated by anthropogenic and natural activities, such as a by-product of 
industrial manufacturing and incomplete combustion of organic materials, respectively [45,46]. 
Human exposure is expected to occur by background, accidental, and/or occupational exposure, 
of which background residues comprise 95% of all exposures [45]. Daily intake of TCDD, 
occurring largely via animal fat ingestion, results in a body burden in the general human population 
estimated to be in the range of 5 to 15 parts per trillion, or 2 pg/g of body fat [44,46]. A previous 
study has estimated that adverse outcomes induced by TCDD can occur with as little as one to two 
orders of magnitude the body burden found in the general population [47].  
It is worth noting that specific life events which result in high mobilization of adipose 
tissue, such as pregnancy and lactation, can result in surges of circulating TCDD levels and 
increased risk of fetal exposure [48–51]. These surges of AHR ligands during gestation and 
perinatal periods are of particular concern to AHR-mediated developmental toxicity.  
AHR-dependent gene expression, indicating prior receptor activation, can also be observed 
even in the absence of classic exogenous/xenobiotic exposure [36].  This finding suggests the 
existence of endogenously derived AHR ligands and/or additional yet-unknown mechanisms of 
AHR-dependent gene expression regulation.  
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The endogenous AHR ligands are much less characterized, relative to the exogenous 
counterparts, though metabolic pathways targeting the amino acid tryptophan and indole have been 
extensively investigated as sources of endogenous AHR ligands [52]. Moreover, bacterial 
pigments, such as phenazines and naphthoquinone phthiocol, have also been shown to be AHR 
ligands and to participate in bacterial defense [53]. This finding is particularly interesting, as recent 
interest in the microbiome as a nexus for gene-environment interactions may bring the endogenous 
AHR physiology further under the spotlight of environmental health research [54–56].  
Ultimately, AHR binding to either xenobiotic or endogenous ligands results in pleiotropic 
yet highly cell type-specific transcriptome changes and in changes in cellular functions [57], some 
of which may be untoward to organismal homeostasis. 
1.2.3. Aryl hydrocarbon receptor-mediated toxicity 
The xenobiotic-activated AHR pathway has been historically implicated in the 
dysregulation of various developmental and homeostatic biological processes. These include 
growth factor signaling, cell cycle regulation, cellular proliferation, differentiation, arrest, and 
apoptosis [58], which ultimately culminate in adverse effects including immunotoxicity, 
hepatotoxicity, carcinogenicity, teratogenesis, and lethality [59–63]. Of interest to the scope of this 
work are the potential teratogenic effects of developmental AHR disruption.  
Two notorious teratogenic effects of developmental AHR disruption, largely described and 
studied via TCDD receptor activation, are palatoschisis (i.e., cleft palate) and hydronephrosis. It 
has been demonstrated that these AHR/TCDD-driven phenotypes are the product of interference 
with many signaling pathways related to cell proliferation, migration, and differentiation 
(myogenesis, osteogenesis, and chondrogenesis) [41,64–66]. Additional teratogenic phenotypes 
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include jaw malformations in zebrafish embryos, impaired tissue regeneration in fish, abnormal 
prostate development in mice, and cardiovascular abnormalities in zebrafish, chickens, mice, and 
potentially humans [66,67]. Overall, the developmental toxicity of AHR ligands is of particular 
concern to humans as pregnant women transfer a fraction of their ligand body burden to the fetus 
during pregnancy and later to the postnatal infant via breastfeeding [50].   
Epidemiological studies have linked high levels of dioxin-like chemical mixtures, most of 
which are AHR ligands, with higher incidences of adverse birth outcomes, such as low birth 
weights, respiratory distress, and pneumonia [68–70]. In addition, epidemiological associations 
have been found between cardiac malformations and the levels of organochlorinated compounds 
in mothers living near incinerators, who were exposed to complex mixtures including dioxins, 
furans, particulates, and heavy metals [71–73]. Specifically, hypoplastic left heart syndrome, a 
type of CHD, has been epidemiologically associated with gestational exposure to AHR ligands 
such as halogenated hydrocarbons, dioxins, and polychlorinated biphenyls [74].  
1.2.4. The constitutive Ahr knockout mouse  
Three independent research laboratories successfully knocked out the AHR in mice, 
namely the laboratories led by Frank Gonzalez (at the NIH) [75], Chris Bradfield (at the University 
of Wisconsin) [76], and Yoshiaki Fujii-Kuriyama (at the Tohoku University, Japan) [61]. While 
the phenotypes associated with constitutive ablation of the receptor vary somewhat among each of 
the three knockout mouse models, as well as between mice and rats [77], ablation of the receptor 
makes mice immune to the classic TCDD-induced toxic phenotypes, such as lethality, 
immunotoxicity, hepatotoxicity, carcinogenicity, and teratogenesis [59–63,78]. Regardless, the 
Ahr-/- mouse model has provided crucial evidence that TCDD-induced toxicity is AHR-dependent 
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[19]. The early studies using the Ahr-/- have demonstrated that these mice are viable, although with 
limited fertility and reproductive efficiency, and are born with developmental defects in the liver 
and eye vasculatures, impaired immune function, and a striking progressive hypertrophic and 
dilated cardiomyopathy [19,75].  
1.2.5. The aryl hydrocarbon receptor and the cardiovascular system 
Perhaps the most striking illustration of the AHR roles in cardiac development and function 
comes from the constitutive genetic ablation of the receptor in mice. In an early report, all 52 
studied Ahr-/- male and female mice were noted to have progressive cardiomyopathy with 
hypertrophy and focal fibrosis [79]. This finding was pivotal in bringing to light the concept that 
the receptor has an important role in normal physiology (i.e., endogenous functions) of the 
cardiovascular system, and that said roles are independent of exogenous ligands.  
Conversely, exogenous (xenobiotic) ligands of the AHR have been extensively implicated 
in adverse outcomes to the developing and adult cardiovascular system, as evidenced by studies in 
many cell types in vitro [36,80] and in multiple animal species in vivo [41,66,67,81,82]. In these 
experiments, the receptor has been linked to global cardiovascular function and dysfunction via an 
endogenous signaling pathway overseeing a complex regulatory network of target genes for 
cardiogenesis and cardiovascular homeostasis [36], with enduring functions in postnatal cardiac 
physiology, such as cardiac sufficiency, blood pressure regulation [83–85], and cardiovascular 
pathology [86]. 
Furthermore, epidemiological studies have connected exposures to high doses of TCDD, 
the prototypical AHR ligand, with heart disease, including ischemic heart disease [87–89]. Given 
that most, if not all, TCDD effects are believed to be mediated by the AHR, these findings provide 
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strong evidence that environmentally-driven AHR disruption may be an important etiological 
factor in idiopathic CHD and adult heart disease in humans.  
 
1.3. Heart development 
The heart, the first organ to develop and function in the embryo, is a highly specialized 
organ comprised of different cell types which arise from distinct embryonic progenitors during the 
marvelous process of cardiogenesis [90]. The induction of stem cells into cardiogenic mesoderm 
is the quintessential prerequisite for heart development and is heralded by the critical cardiogenetic 
transcription factor Nkx2.5 [91,92] and subsequently regulated by Nodal, bone morphogenetic 
protein (Bmp), Wnt, and fibroblast growth factors (Fgf) [90], among others. Collectively, over 40 
genes tightly orchestrate heart development, maturation, and function [3,11,93]. In addition, 
through waves of cell migration, three populations of extra-cardiac cells are assimilated into the 
heart: pro-epicardium from the mesenchyme of the septum transversum; dorsal mesocardium, 
which is incorporated into the prospective atria from the body wall; and cardiac neural crest cells, 
which migrate through the pharyngeal arches to the outflow tract [94]. For comprehensive and 
detailed illustrations of cardiogenesis, the reader is encouraged to refer to the work by Savolainen 
et al [94] and de Boer et al [95].   
At the time a regular beat becomes present, the mouse heart is comprised of approximately 
5,000 multi-potent cells.  This anlage will have expanded over the next 11 days in utero to a 
complex organ comprised of approximately 1,000,000 oligo-potent or terminally differentiated 
cells by the time the mouse pup is born [95]. During this process, the cardiogenic mesoderm 
differentiates into cardiomyocyte precursors in the primitive streak and migrate anterio-laterally 
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to form a bilateral pair of cardiogenic plates (myocardial primordium), which in the mouse embryo 
occurs at embryonic day (E) 7.5 [94,95]. Immediately subjacent to this structure, endothelial cells 
differentiate to form right and left endocardial heart tubes, which then align in parallel and fuse 
across the ventral midline to form a single irregularly-beating heart tube by approximately E8.25 
[105], which contains rostral arterial (aortic sac) and caudal venous poles (right and left sinus 
horns), and is sufficient to establish a primitive circulation through the embryonic body and 
connecting to the yolk sac (i.e., primitive placenta).  
By E9.0, the beating becomes regular with the venous pole acting as the initial pacemaker 
[94]. The beating heart tube then lengthens, loops to the right, and undergoes fusion and septation 
to form distinct primitive atria and ventricles [95]. From E9.5 through birth, the heart undergoes 
pronounced modeling and remodeling, septation, valve formation, and myocardial compaction 
yields the four chambers of the heart, as well as the two separate outflow channels, the aorta and 
the pulmonary trunk, respectively [94].  
 Heart development is an intricate process dictated by the tight orchestration of molecular 
events involved in cellular differentiation, proliferation, and migration, all of which can be derailed 




The name mitochondrion is derived from the Greek words for “grain” (chondros) and 
“thread” (mitos), and implies mitochondrial morphology ranges from “cigars” to an interconnected 
network comparable to the endoplasmic reticulum [96]. Mitochondria are organelles essential for 
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tissue homeostasis by participating in metabolism (especially in the generation of energy 
intermediates), cell signaling, and cell death [97]. Not surprisingly, these organelles are also 
critical for developmental homeostasis, as evidenced by embryonic lethality when one or more 
genes related to mitochondrial maturation and fusion are silenced in mice [97].  
The general ultrastructure of the mitochondria is comprised of an inner and outer 
membrane, an intermembrane space, and a central matrix. Along the inner membrane 
invaginations (so-called cristae) reside five complexes of the electron transport chain, which carry 
on oxidative phosphorylation [96].  Briefly, Complexes I and II transfer electrons from NADH 
and FADH2, generated by the Tricarboxylic Acid Cycle (so-called Krebs Cycle) in the 
mitochondrial matrix, through the electron transport chain to reduce molecular oxygen to water. 
The electrochemical gradient generated in the process is tapped by Complex V to convert ADP 
and inorganic phosphate to ATP, the energy currency of most differentiated cells [96].  
In the developing heart, mitochondria are initially immature and inefficient and must 
undergo a transition into more complex organelles to ensure proficient and competent cardiac 
development. Mitochondria increase or decrease in size and numbers by processes termed fission 
and fusion [96]. In fact, cardiomyocyte maturation has been shown to be tightly associated with 
mitochondrial maturation, such that inhibition of one results in the blockade of the other [98]. In 
the adult, cardiac metabolic demand is even higher and more critical as evidenced by the 
catastrophic clinical consequences of myocardial bioenergetic loss, such as that which occurs 
during myocardial infarction [96]. The embryonic myocardium initially relies on anaerobic 
glycolysis as its main source of energy, later switching to aerobic respiration once the placental 
circulation has been established, and these changes are also tightly related to particular 
cardiogenesis milestones [96].  
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Mitochondrial biogenesis, maturation and function are intricately connected with heart 
development and are vital to sustain cardiogenesis and postnatal cardiac function. Consequently, 







2. Hypothesis  
The overarching hypothesis of this dissertation is that developmental disruption of the 
endogenous AHR program in vivo, either by constitutive genetic ablation or by an exogenous 
ligand exposure, using a mouse model, results in molecular, structural, and functional cardiac 
abnormalities in the embryo which persist and progress in the adult.  
This hypothesis was built upon the above-reviewed body of literature and previous work 
from the Puga Laboratory at the University of Cincinnati, which have demonstrated that activation, 
inhibition, or knockdown of Ahr during mouse embryonic stem (ES) cell differentiation all 
significantly inhibit the formation of contractile cardiomyocyte nodes [36], which may be used as 
an in vitro surrogate for cardiotoxicity assessment. In the first part of this work, we developed a 
mouse model of in utero environmental AHR disruption to characterize, at key cardiogenesis 
developmental windows, the resulting molecular, structural, ultrastructural, and functional cardiac 
phenotypes of naïve Ahr knockout mice (Ahr-/-) embryos and either naive wild-type (Ahr+/+) 
embryos or Ahr+/+ embryos exposed in utero to a potent AHR agonist; all details of this study are 
described in Chapter 2. In the second part of this work, we tested whether the observed AHR 
disruption-related effects have the potential to impair postnatal cardiovascular maturation and 
function, in analogy to the adult cardiac insufficiency resulting from congenital heart disease in 
humans. To verify that altered adult cardiovascular structure and function can be experimentally 
linked to gestational disruption of the AHR signaling pathway in vivo, we compared the molecular, 
structural, ultrastructural, and functional cardiac phenotypes of adult naïve Ahr knockout mice 
(Ahr-/-) with those of wild-type naïve (Ahr+/+) and Ahr+/+ adult mice exposed in utero to TCDD; 
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Congenital heart disease is the most common congenital abnormality and one of the leading 
causes of newborn death throughout the world. Despite much emerging scientific information, the 
precise etiology of this disease remains elusive. Here we show that the aryl hydrocarbon receptor 
(AHR) regulates the expression of crucial cardiogenesis genes and that interference with 
endogenous AHR functions, either by gene ablation or by agonist exposure during early 
development, causes overlapping structural and functional cardiac abnormalities that lead to 
altered fetal heart physiology, including higher heart rates, right and left ventricle dilation, higher 
stroke volume, and reduced ejection fraction. With striking similarity between AHR knockout 
(Ahr-/-) or activation (agonist-exposed Ahr+/+ embryos), in utero disruption of endogenous AHR 
functions converge into dysregulation of molecular mechanisms needed for attainment and 
maintenance of cardiac differentiation, including the pivotal cardiogenic transcription factor 
NKX2-5, energy balance via oxidative phosphorylation and tricarboxylic acid cycle (TCA), and 
global mitochondrial function and homeostasis. Our findings suggest that AHR signaling in the 
developing mammalian heart is central to the regulation of pathways crucial for cellular 
metabolism, cardiogenesis and cardiac function, which are potential targets of environmental 





Congenital heart disease (CHD) is the most common congenital abnormality and one of 
the leading causes of newborn death in developed and many developing countries. 
Notwithstanding a wealth of emerging scientific information, the precise etiological basis 
underlying the majority of CHD cases remains elusive.  Recent epidemiologic studies estimate that 
less than 15% of cases of CHD can be traced to known causes of Mendelian inheritance [45], 
suggesting the likelihood that environmental agents operative at the time of heart formation may 
be critical etiological contributors to the disease [14;20;47]. A multifactorial pathogenesis with 
interplay between genetic, epigenetic and environmental factors would be consonant with the 
tenets of the theory of the Developmental Origins of Health and Disease, which postulates that the 
environment in the uterus enduringly shapes the structure, function and metabolism of the adult 
organism [4]. Accordingly, damage resulting from environmental insults during fetal life may be 
at the heart of congenital and adult-onset cardiac diseases. 
Some such insults may be the consequence of exposure to xenobiotic environmental agents 
that signal through the aryl hydrocarbon (Ah) receptor (AHR). Developmental interference with 
endogenous AHR functions has been shown to adversely affect the cardiovascular system in 
various experimental models, both in vitro [16;49] and in vivo [2;3;5;7;15;30;51], and have 
implicated the AHR in the etiology of cardiovascular disease. Significantly, maternal exposure to 
environmental teratogens was proposed more than 50 years ago to contribute to and potentially 
explain a large proportion of congenital heart disease [26], yet little direct evidence has since been 
developed that tested this hypothesis. 
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Cardiogenesis is the product of the precise orchestration of innumerable gene networks 
regulating developmental commitments towards cellular differentiation, migration, proliferation, 
and death [33;40;46]. In this setting, the developing heart has been found to be exquisitely sensitive 
to AHR disruption [3;30;43] likely due to the critical endogenous role of this receptor in 
embryogenesis. Genome-wide studies in mouse embryonic stem (ES) cells have shown that 
disruption of endogenous AHR expression perturbs cardiomyocyte differentiation, underscoring a 
critical role for the receptor in a complex regulatory target network for cardiogenesis and 
cardiovascular homeostasis [49]. The endogenous AHR signaling has also been shown to carry 
out enduring functions in postnatal cardiac physiology, such as cardiac sufficiency and blood 
pressure regulation [24;34;52], and cardiovascular pathology [6]. These observations suggest that 
AHR contributes at multiple levels to global cardiovascular health, though whether cardiac 
pathology can be experimentally linked to gestational disruption of the AHR signaling pathway 
remains to be determined. 
As a ligand-activated transcription factor and a member of the basic-region-helix-loop-
helix PER/ARNT/SIM (bHLH-PAS) superfamily, the AHR is classically known to mediate the 
ligand-dependent induction of xenobiotic metabolism programs, such as controlled by the CYP1 
family of cytochromes P450 and several phase II detoxification enzymes [30]. Members of the 
bHLH-PAS protein superfamily differentially regulate various signaling pathways related to 
development and homeostasis [17]. The AHR pathway is further implicated in the regulation of 
several developmental and homeostatic biological processes, such as immune response, growth 
factor signaling, cell cycle proliferation, differentiation, arrest, and apoptosis [3;31;32;43]. 
Importantly, the AHR is also a key environmental sensor [11], and, when activated by exogenous 
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ligands during mouse development, recapitulates some of the phenotypes observed in mice with 
constitutive ablation of the Ahr gene [3].  
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin; dioxin) is one such exogenous ligand and one 
of the most potent AHR agonists [35]. After ligand-induced activation, AHR induces the 
expression of its target genes, followed by proteasome-dependent degradation leading to overall 
depletion of AHR in the cell [8;13]. It is hypothesized that “post-exposure AHR down-regulation” 
may mimic an AHR-null condition. Alternatively, it is speculated that the exogenous (xenobiotic) 
ligands may compete with the endogenous (physiological) ligands, thereby diverting AHR from 
its normal biological functions [12]. Which of the endogenous AHR functions are perturbed by 
toxic chemicals remains to be determined.   
To address the hypothesis that developmental disruption of the endogenous AHR program 
by either constitutive ablation or by an exogenous ligand exposure would result in cardiac 
abnormalities in vivo, we sought to characterize at key cardiogenesis developmental windows the 
molecular, structural, ultrastructural, and functional cardiac phenotypes of naïve Ahr knockout 
mice (Ahr-/-) embryos and either naive wild-type (Ahr+/+) embryos or Ahr+/+ embryos exposed in 
utero to a potent AHR agonist.  
3. Materials and Methods 
3.1. Animals and Treatments 
All experiments were conducted using the highest standards of humane care in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals and were approved in advance 
by the University of Cincinnati Institutional Animal Care and Use Committee. Age-matched Ahr+/+ 
and Ahr-/- C57BL/6J female mice were mated overnight with Ahr+/+ and Ahr-/- C57BL/6J male 
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mice, respectively. Maternal gestational exposure to the prototypical AHR ligand TCDD was 
performed once via oral gavage at key developmental time points as previously described (Wang 
et al. 2013) and is illustrated in detail in Supplemental Fig. S1A. Dams were treated by oral gavage 
with either corn oil (vehicle) or with TCDD at doses of 0.1, 0.5, 1, 2.5, 5, or 50 μg/kg, which based 
on previous determinations are estimated to correspond to 0.034, 0.17, 0.34, 0.85, 1.7, and 17 ng, 
respectively, to individual embryos [50]. For the sake of clarity, all developmental samples are 
referred to as embryos, even though the later time points used (E15 and older) would technically 
qualify for the term fetus. Embryo samples were collected on E13.5, E15.5, and E18.5. To assess 
for potential toxic effects from these exposure levels, maternal and F1 body and organ weights 
were measured and litter size and sex ratios recorded. The overall outcomes of gestational AHR 
disruption, be it by receptor ablation or potent agonist exposure, are detailed in Fig. S1B-I.  
3.2. Organ and embryo weights  
Following euthanasia of the dam by carbon monoxide asphyxiation, gravid uteri were 
immediately harvested, and individual embryos were freed from extra-embryonic membranes. 
Embryos were gently blotted to remove excess fluids and weighed using a high-definition scale. 
The maternal and embryo liver weights were determined by isolating the liver free of other tissues, 
gently blotting to remove excess fluids, and weighing. Dry embryo body and embryo heart weights 
were determined following 48-h incubation in a drying oven at 60°C. Organ weights were 
normalized to body weight.  
3.3. Histology, Immunohistochemistry, and Microscopy 
Tissues samples were fixed for 48 hours in freshly prepared 4% paraformaldehyde (pH 
7.4) at 4 °C (Sigma-Aldrich), rinsed in serial ethanol dilutions, and then routinely processed into 
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paraffin for histology. Immunostaining and routine hematoxylin and eosin (H&E) staining was 
performed using standard protocols as previously described [25]. For immunohistochemistry, 
polyclonal primary antibodies against AHR (anti-rabbit, SA-210, Enzo), NKX2-5 (anti-rabbit, 
Ab35842, Abcam), and Ki-67 (anti-rabbit, Millipore) were used. Immunostaining quantification 
was performed using the color deconvolution plugin and threshold functions of the ImageJ 1.47h 
(National Institutes of Health) to determine the percentage of nuclei labeled (% positive index). 
Qualitative immunohistochemical analyses were performed on 4-5 embryos from at least three 
litters per experimental condition. Morphometric analyses were carried out in 3 serial sections of 
at least 4-5 embryos from at least three litters per experimental condition using the Zen 
morphometry suite (Blue Edition version 1.0.0.0, Carl Zeiss Microscopy). Briefly, for each section 
manual measurements using the line function were taken of the ventricle wall perpendicular to the 
apex-base axis of the heart, to include the trabecular and compact myocadium (total thickness) or 
only compact myocardium (compact ventricle thickness).     
3.4. Transmission electron microscopy  
At least three hearts per treatment group were immediately fixed in phosphate-buffered 3% 
glutaraldehyde (pH 7.4) at 4°C for 24 hours and submitted to the Pathology Research Core at 
Cincinnati Children’s Hospital Medical Center for routine sample processing and sectioning for 
electron microscopic examination. Samples were washed three times in 0.1 M cacodylate buffer, 
pH 7.2, and post-fixed in 1% osmium tetroxide buffered with 0.1 M cacodylate, pH 7.2, at 4°C for 
1 h. After dehydration in serial alcohol and propylene oxide solutions, samples were infiltrated 
with and embedded in LX112. One-micron-thick sections were stained with toluidine blue. Ultra-
thin section were stained with uranyl acetate (0.5%) and lead citrate (3%). Imaging was performed 
on a transmission electron microscope (7600; Hitachi). Five non-overlapping 
36 
 
ultraphotomicrographs per grid were taken at 8000X, 25000X, and 70000X magnifications and 
evaluated using Image J 1.47h software.   
3.5. Mitochondria quantification  
The relative amounts of embryo heart mitochondria (ratio of mitochondrial DNA [mtDNA] to 
nuclear DNA [nDNA]) were determined using a RT-PCR method as previously described [41]. 
The targets were the genes coding for the nuclear cytochrome P450 Cyp1a1 and for the 
mitochondrial nicotinamide adenine dinucleotide dehydrogenase-5 (Nd5). Primers for the Cyp1a1 
promoter region at -0.9 kb were: forward: 5'- AGGCTCTTCTCACGCAACTC -3’; reverse: 5'- 
TAAGCCTGCTCCATCCTCTG -3’. Primers for Nd5 were: forward 5’-TGG ATG ATG GTA 
CGG ACG AA-3’; reverse 5’-TGC GGT TAT AGA GGA TTG CTT GT-3’.  
3.6. RNA.seq analysis 
Embryo hearts were microdissected into right atrium, left atrium, and ventricles with the 
assistance of a dissecting microscope (Supplemental Fig. S4A). Individual samples were stored in 
200 µL of RNA-Later at -80°C until RNA extraction. Total RNA was extracted with the RNeasy 
Mini Kit (QIAGEN) with Proteinase K and DNAse steps working by the manufacturer’s 
instructions. All steps of library construction, cluster generation, and HiSeq (Illumina) sequencing 
were performed with biological triplicate samples by the Genomics Sequencing Core of the 
Department of Environmental Health, University of Cincinnati. Differential gene expression 
analyses between Ahr+/+ and Ahr-/- embryos or between AHR ligand-exposed and naïve Ahr+/+ 
embryos was performed separately at each of the three different developmental time points (E13.5, 
E15.5, and E18.5). Statistical analyses were performed to identify differentially expressed genes 
for each comparison using the negative-binomial model of read counts as implemented in the 
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Bioconductor DESeq package. Significant genes were selected based on a false-discovery rate–
adjusted p-value < 0.0001. RNA.seq data was further analyzed using Ingenuity Pathway Analysis 
(IPA; Ingenuity® Systems, http://www.ingenuity.com). 
3.7. Embryo (in utero) echocardiography 
To evaluate for functional abnormalities, we performed a full high frequency 
echocardiographic study of the embryos in utero at E15.5. The study was carried out as previously 
described [39] using the Vevo 2100 Ultrasound system equipped with a MS700 30–70 MHz probe 
and post-processed at a separate workstation (Visualsonic, Vevo 2100, v1.1.1 B1455) using a 
coded (“blinded”) analytical paradigm (Supplemental Fig. S2). The B-mode, color and Doppler 
images were analyzed for valvular function and structural abnormalities, while the M-mode images 
were post-processed for cardiac functional analysis, including ventricular size, ejection fraction 
and cardiac output.  
3.8. Statistical Analyses 
Statistical analyses were done at each time point using unpaired two-tailed t-test of Ahr-/- or TCDD-
exposed Ahr+/+ mouse embryos relative to naïve Ahr+/+ embryos.  
 
4. Results  
4.1.  The AHR is largely nuclear during early differentiation.  
  To determine whether AHR plays a role in cardiogenesis, we probed matching sections of 
hearts from mouse embryos exposed to TCDD or vehicle control for AHR expression at key 
cardiogenesis time points, namely E7.5, E9.5, and E11.5.  AHR was detected at embryonic day 
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E13.5, the earliest time point measured. In vehicle-exposed controls, approximately 12% of the 
ventricular cells were positive for AHR expression, which was mostly localized to the nucleus of 
cells lining the developing epicardium, with little or no evidence of cytoplasmic localization (Fig. 
1A, B). In TCDD-exposed embryos, the number of AHR positive cells was reduced to 
approximately one-half of the control value (Supplemental Fig. S3), consistent with the concept 
that ligands promote receptor down-regulation. At E15.5, nuclear AHR-positive cells decreased 
significantly both in control and TCDD-treated embryos, though to a greater extent in the latter, 
and by E18.5 the amount of AHR was much less abundant in the nucleus (Fig. 1A, B). The 
detection of AHR in the nucleus of early developing hearts suggests that the AHR functionally 
contributes to heart formation during a critical window of development and that exogenous ligands, 
which attenuate the nuclear localization of the endogenous AHR at this developmental time, may 
interfere with the AHR endogenous role in cardiogenesis.   
4.2. Developmental disruption of AHR signaling alters the structure of the developing 
myocardium.  
Activation of the AHR pathway by exogenous ligands has been associated with disruption 
of developmental and homeostatic biological processes, including growth factor signaling, cell 
cycle proliferation, differentiation, arrest, and apoptosis [31]. To determine whether altered AHR 
signaling during cardiogenesis caused structural abnormalities in the developing heart, we 
examined embryonic hearts from naïve Ahr-/- mice and from wild type mice gestationally exposed 
to TCDD or to vehicle.  Exposure to TCDD in utero resulted in decreased cross-sectional left wall 
thickness at E13.5, E15.5, and E18.5, whereas Ahr ablation decreased left wall thickness at E13.5 
and E15.5, but not E18.5 (Fig. 2A). Histomorphometric assessment of serial sections showed that 
Ahr-/- and ligand-exposed embryos had thinner left ventricular myocardium at all measured time 
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points, except at E18.5 for Ahr-/-  embryos (Fig. 2B), despite the fact that these hearts had a relative 
increase in the thickness of the left ventricle compact myocardium (Fig. 2C and Supplemental Fig. 
S4). Ligand-exposed Ahr+/+ embryos had decreased heart weight relative to body weight at E13.5 
(Fig. 2D). The Ahr-/- embryos had reduced heart weight at E13.5, increased heart weight at E15.5, 
and unchanged heart weight at E18.5. Altogether, these data support the conclusion that disruption 
of AHR signaling in utero alters the developing myocardium structure, composition, and mass. 
To determine whether the observed decreases in myocardium mass were the consequence 
of a measurable decrease in cell proliferation, we probed sections of embryonic heart tissue for 
expression of the Ki-67 antigen, a proxy for cellular proliferation [36]. The Ki-67 index was 
determined throughout the myocardium to include right and left atria and ventricles, as well as the 
interventricular septum. Exposure of Ahr+/+ mice to TCDD induced a significant increase in 
cellular proliferation across sub-anatomical areas of the embryo hearts at E13.5, with no significant 
differences at E15.5 and E18.5. On the other hand, Ahr-/- hearts showed significantly decreased 
proliferation indices at all three time points tested (Fig. 2E-F). Masson’s trichrome histochemistry 
revealed no significant differences in interstitial collagen deposition (data not shown), suggesting 
that remodeling of the interstitial matrix was not a major contributor to the observed effects. The 
large differences that we observe in proliferation indices suggest that the alterations in myocardial 
composition and mass could be related to the observed decrease of cardiomyocyte proliferation in 
Ahr-/- hearts, but less so in hearts of Ahr+/+ ligand-exposed mice.  
4.3. Developmental AHR disruption affects embryonic heart function. 
To ascertain whether developmental AHR disruption would impair embryonic heart 
function, we sought to determine if and to what extent echocardiographic parameters of heart 
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physiology were altered by genetic or functional disruption of the AHR. Using in utero 
echocardiography at E15.5, we found that TCDD exposure to Ahr+/+ embryos was associated with 
significantly higher heart rates as compared to those in hearts of naïve Ahr+/+ mice (Fig. 3A). 
Conversely, ablation of the Ahr gene was associated with significant right and left ventricle dilation 
(Fig. 3B), higher stroke volumes (Fig. 3C), and reduced ejection fraction (Fig. 3D) relative to naïve 
Ahr+/+ hearts. A trend that did not reach statistical significance was also noted for decreased 
ventricle wall thickness with either ablation of the Ahr gene or TCDD exposure in Ahr+/+ mice 
(Fig. 3E-F), consistent with the observation of decreases in embryonic heart weight and 
histological evidence of myocardial thinning. Altogether, in utero echocardiographic assessment 
of embryonic hearts identified significantly altered parameters and trends, thereby suggesting a 
decrement in cardiovascular function which, although not presently overt, occurs at a critical time 
of embryonic development.  
4.4. Interference with AHR signaling disrupts the expression of key networks involved in 
cardiogenesis and cardiac homeostasis. 
The structural and functional changes in the embryo hearts resulting from Ahr ablation or 
Ahr activation by ligand support the hypothesis that the AHR may have a regulatory role in 
cardiogenesis, to the extent that disruption of differential AHR signaling causes the morphological 
changes observed. To identify and characterize which AHR-regulated genes and pathways were 
involved in heart development, we carried out RNA next-generation sequencing (RNA.seq) of 
naïve Ahr+/+, Ahr-/-, and ligand-exposed Ahr+/+ embryonic hearts, at the three distinct 
developmental milestones in cardiogenesis that we had followed structurally.  For these analyses, 
we studied left atrium, right atrium, and ventricles separately (Supplemental Fig. S5A).  
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Loss of the Ahr gene de-repressed overall gene expression, as Ahr-/- embryo hearts 
generally had higher numbers of differentially expressed genes compared to ligand-exposed Ahr+/+ 
hearts. Overall, the majority of differentially expressed genes in either ligand-exposed Ahr+/+ or 
Ahr-/- hearts, relative to naïve Ahr+/+ hearts, were observed at the E15.5 time point in the right 
atrium. The ventricles showed few differentially expressed genes after ligand exposure and both 
compartments, ventricles and atria, showed fewer changes at E18.5 (Supplemental Fig. S5B). 
Differential expression in the left atrium relative to the right atrium was more limited at all three 
time points (Supplemental Fig. S6). Functional annotation of the genes significantly altered at 
E15.5 in the right atrium and ventricles of Ahr-/- embryos and in ligand-exposed Ahr+/+ embryos 
indicated that a large subset of these genes belong to biologically relevant pathways related to 
heart formation and function. Specifically, these were pathways implicated in cardiogenesis, 
NKX2-5 signaling, AHR signaling, congenital heart anomalies, homeobox cardiac transcription 
factors, cardiac homeostasis and function, and mitochondrial dysfunction (Fig. 4A-B). 
Remarkably, the identity and the direction—induction or repression—of gene expression changes 
in the E15.5 right atria (Fig. 4A), were strikingly similar between Ahr-/- and ligand-exposed 
Ahr+/+embryos.  
Further analysis of RNA.seq data on the basis of the biological relevance of the 
differentially expressed genes revealed significant ontogenies populated by genes, such as Shox2, 
Tbx2, Tbx5, Nppa, Gja1, Hey2, Irx4, Myl2, and Hand1, that were highly concordant between Ahr-
/- and TCDD-exposed Ahr+/+ mice, all playing critical roles in cardiogenesis and congenital heart 
disease. A high degree of directional and identity overlap was observed among these selected 
critical cardiogenesis genes (Fig. 4C and Supplemental Table S1). Collectively, differentially-
expressed genes populated Ingenuity® IPA’s networks belonging to, among others, cardiac 
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hypertrophy, congenital heart anomaly, cardiac necrosis/cell death, cardiac fibrosis, and cardiac 
dilation (Fig. 4D and Supplemental Fig. S7). It appears that in the developing heart, receptor 
ablation or its activation by exogenous ligands similarly disrupt the molecular networks involved 
in heart formation and function. Seemingly, the changes in embryonic heart transcriptome 
resulting from Ahr ablation or ligand-mediated activation disrupt common molecular features and 
pathways that direct cardiac function with a high degree of overlap and directional agreement, 
especially during development of the right atrium at E15.5.  
4.5. Developmental AHR ligand exposure reduces the transcriptional activity of NKX2-5 
within the developing heart.  
Transcriptome sequencing of embryonic hearts revealed that AHR disruption resulted in 
differential expression of the NKX2-5 signaling network, in agreement with our recent report that 
developmental loss of AHR homeostasis, as caused by exposure to ligand, affects differentiation 
of ES cells into cardiomyocytes by disrupting the expression of key homeobox regulators, 
including Nkx2-5 [49]. The homeodomain factor Nkx2-5 is a central regulator of cardiogenesis that 
specifies the spatial definition, formation and maintenance of heart structures [23;37]. The critical 
role that this gene plays in cardiogenesis is attested to by the fact that Nkx2-5 hypomorphic mice 
recapitulate human CHD and that mutations in the homologous NKH2-5 human gene are 
commonly found in human CHD cases [29]. We therefore sought to determine whether in vivo 
gestational disruption of AHR homeostasis would also affect the regulation of Nkx2-5 expression 
at the transcript and protein levels. Analysis of the right atrium transcriptomes of Ahr-/- and ligand-
exposed Ahr+/+ embryos revealed a high degree of similarity of both profiles (Supplemental Table 
S2) with the previously-published cardiac transcriptome of Nkx2-5 mutant mice [29]. The common 
pattern, involving key cardiogenesis genes, was characterized by decreased expression of Nppb, 
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Myl2, and Irx4 and increased expression of Igfbp5, Pdgfra, Tnc, Isl1, Tbx5, and Fgf10. 
Accordingly, immunohistochemical staining of embryonic hearts at E15.5 showed a significant 
decrease of the number of NKX2-5 positive nuclei in embryonic hearts of Ahr-/- and of ligand-
exposed Ahr+/+ mice (Fig. 5A, quantified in Fig. 5B; additional compartment-specific NKX2-5 
expression is shown in Supplemental Fig. 8).  Collectively, these data indicate that gestational 
AHR receptor ablation or its activation by ligand exposure is responsible for decreased nuclear 
localization of the cardiogenic transcription factor NKX2-5, and the consequent disruption of the 
Nkx2-5 signaling network.  
4.6. Developmental AHR disruption-driven transcriptome dysregulation affects 
mitochondria structure and abundance. 
AHR disruption-driven transcriptome dysregulation resulted in down-regulation of 
mitochondrial function pathways (Fig. 6A) and genes controlling critical biological processes 
involving energy generation and handling, such as oxidative phosphorylation (Fig. 6B) and the 
TCA cycle (Fig. 6C) in Ahr-/- and ligand-exposed Ahr+/+ embryonic hearts.  Moreover, 
mitochondrial Complexes I through V were collectively suppressed in both Ahr-/- (Supplemental 
Fig. S9) and ligand-exposed Ahr+/+ (Supplemental Fig. S10) embryonic hearts. As in the case of 
cardiac development genes, the identity and direction of change in mitochondrial function genes 
were largely affected identically in embryo hearts of Ahr knockout and ligand-treated Ahr+/+ mice.  
Notably, at a time when expression of genes controlling oxidative energy metabolism must 
increase to cope with increased energy requirements in the developing embryo [22], the effect of 
either Ahr ablation or ligand exposure to Ahr+/+ mice could greatly impair mitochondrial 
homeostasis in the embryonic heart. Hence, to study the structural consequences of mitochondrial 
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dysfunction, embryo hearts at E13.5, E15.5, and E18.5 were examined for the abundance and 
quality of heart mitochondria. A measure of the ratio of mtDNA to nuclear DNA, coupled with 
ultrastructure studies, revealed a higher abundance of mitochondria in hearts of Ahr-/- and ligand-
exposed Ahr+/+ mice. Specifically, at E15.5 and E18.5, the copy number of mitochondria was twice 
and three times higher, respectively, in Ahr-/- and in ligand-exposed Ahr+/+ mice than in naïve 
Ahr+/+ mice (Fig. 7A). Ultrastructurally, the increased mitochondria numbers were evident by their 
higher density within the embryonic cardiomyocyte sarcoplasm (Fig. 7B). Furthermore, individual 
or clusters of mitochondria showed ultrastructural features of stress and degeneration, as evidenced 
by focal to global swelling, loss of matrix density, as well as cristae unpacking, disorganization 
and cristolysis, which appeared to affect higher numbers of mitochondria in ligand-exposed Ahr+/+ 
hearts. These changes were observed at E13.5 in ligand-exposed Ahr+/+ hearts as well as at E15.5 
and E18.5 in either ligand-exposed Ahr+/+or Ahr-/- embryo hearts (Fig. 7B).  Overall, these data 
indicate that the mitochondrial dysfunction postulated on the basis of transcriptome analyses 
correlated with and was substantiated by quantitative and qualitative structural changes to the 
embryonic heart mitochondria. Alterations in mitochondria abundance and ultrastructure were 
likely compensatory responses to the suppressed mitochondria functional networks.  
5. Discussion 
In this study we show that interference with endogenous AHR functions during early 
development, through gene ablation or exposure to TCDD, perturbs cardiogenesis and leads to 
molecular and structural cardiac abnormalities, and departure from functional homeostasis. These 
developmental cardiac effects take place at TCDD doses well below the well-characterized 
teratogenic doses that cause cleft palate and hydronephrosis. By targeting the post-implantation 
period of organogenesis, gestational exposure to ligand was tailored to optimally address the 
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consequences of AHR disruption at critical times of the cardiogenesis program. Maternal exposure 
to TCDD at E7.5 impacts the induction of cardiogenic mesoderm from splanchnic mesoderm and 
the critical initiation events in cellular commitment towards cardiomyogenesis. Exposure at E9.5 
and E11.5 impinges on the formation of atria and ventricles from the elongated and looped heart 
tube, which needs to further proliferate and mature prior to chamber septation [9]. AHR disruption 
during these critical events, be it from ablation or by ligand-induced down-regulation, provided 
the means to characterize the role of the AHR in gene-environment interactions in cardiogenesis.  
Consistent with a lack of overt systemic embryo toxicity, no effects to litter size or embryo 
body weight were observed.  Yet, the AHR/TCDD axis had a significant role in the gross 
anatomical development of the heart, causing a significant decrease of total ventricle thickness and 
weight late in gestation. AHR ligand exposure also altered the composition of the ventricular wall, 
increasing the thickness of the compact myocardium and reducing the total myocardial mass, as 
previously reported [43]. These morphological changes paralleled increases in cell proliferation at 
E13.5 and E18.5, possibly representing a compensatory mechanism to rescue a decrease in cell 
proliferation rate prior to E13.5. Conversely, Ahr gene ablation resulted in decreased cell 
proliferation across all developmental time points measured, perhaps as part of the mechanism 
underlying the decreased heart weight and wall thickness associated with constitutive ablation of 
the receptor.  Ultimately, disruption of endogenous AHR functions in utero and structural 
abnormalities correlated with echocardiographic alterations of fetal heart function, characterized 
by higher heart rates in ligand exposed embryos and right and left ventricle dilation resulting in 
higher stroke volume though reduced ejection fraction in knockout embryos. 
In line with our findings in ES cells [49], the AHR is mostly nuclear in the developing 
mouse heart in a high percentage of cells at E13.5 and E15.5, even in the absence of an exogenous 
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ligand. At this time, however, the localization appears to be mainly in cells lining the internal and 
external surface of the developing myocardium, endocardium and epicardium respectively, and 
most consistent with an endothelial identity. In contrast, at E18.5, the localization is predominantly 
cytoplasmic in cardiac troponin T-positive cardiomyocytes, in agreement with its localization in 
many cultured cell lines and in adult mouse liver. At the earlier time points, ligand exposure 
decreased the level of nuclear localization, conceivably by export from the nucleus and 
proteasomal degradation, as shown in in vitro systems [35]. These results strengthen the view that 
at early development times the AHR has an endogenous function that may be a target for disruption 
by exposure to exogenous ligands, such as TCDD. AHR nuclear localization may be the 
consequence of activation by endogenous mechanisms, either ligand-independent or dependent on 
an endogenous ligand.  In either case, it appears that the AHR may have a role in heart development 
that is independent of exogenous ligand-mediated activation and that TCDD, an exogenous ligand, 
may sequester it away from its endogenous function. While the AHR is a recognized hub in 
gene/environment interactions, the developmental spatial and temporal patterns of AHR 
expression have been only partially identified in mammals [1;19]. The AHR subcellular location 
during development is incompletely characterized, loosely described as either cytoplasmic, 
nuclear, or a combination thereof, in a time-, cell/tissue-, and ligand-binding status-dependent 
fashion. Thus, the homeostatic pattern of AHR expression in naïve tissues delineated in this study 
advances our understanding of the contributions of this protein to cardiac morphogenesis and 
physiology [30;52].  
The hearts of Ahr-/- and ligand-exposed Ahr+/+ embryos showed decreased nuclear 
expression of the cardiogenesis regulator NKX2-5, as previously observed in vitro [30;52]. This 
is of particular importance as decreased expression of the Nkx2-5 gene, in and of itself, brings 
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about haploinsufficiency of its product, with resultant pathological phenotypes such as congenital 
heart disease and cardiomyopathies [29]. In utero, AHR disruption not only repressed Nkx2-5 
expression but also derailed the expression of Nkx2-5 regulated genes and of genes controlling 
pathways responsible for attainment and maintenance of cardiac differentiation, homeostasis, and 
function. For the most part, the identity and direction of the resulting gene expression changes 
were strikingly similar between Ahr-/- and ligand-exposed Ahr+/+embryos and were annotated to 
ontogenies of cardiogenesis, cardiac function, congenital heart anomaly, homeobox transcription 
factors, AHR signaling, Nkx2-5 signaling, and isoproterenol response (i.e. functional stress) 
pathways, central to cardiomyocyte homeostasis.  
In addition to the effects in cardiogenesis pathways and Nkx2-5 signaling, AHR disruption 
also down-regulated the expression of genes encoding subunits of all five mitochondrial 
respiratory chain complexes (MRC) and other genes regulating oxidative phosphorylation and the 
TCA cycle, all playing a central role in essential biological processes through the generation of 
reactive oxygen and production of cellular energy substrates. Mitochondrial defects have been 
implicated in various diseases, including cardiovascular disease [28;48], but less is known about 
how they specifically impact the mechanisms involved in early embryonic development. Knockout 
of the mitochondrial Tfam transcription factor A is known to block transcription of all 13 
mitochondrial DNA-encoded MRC subunits, causing embryonic lethality [21].  While AHR 
disruption is not embryonic lethal, given the extent of the resulting gene expression changes, we 
might expect that energy balance, including ATP yield, proton-motive force, respiratory rate and 
mitochondrial membrane potential will be perturbed by AHR disruption, thereby causing a 
compensatory increase of aerobic glycolysis in the cytoplasm, accompanied by formation of lactate 
from pyruvate.  Although cardiomyocytes can efficiently produce energy from lactate [44], tight 
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regulation of energy generation and handling is paramount for the maintenance of heart 
homeostasis and is likely to be impaired by AHR disruption.    
Furthermore, AHR disruption has previously been shown to cause mitochondrial 
dysfunction [28;38;42] with resulting altered expression of nuclear encoded mitochondrial genes 
[10] and increased abundance of mitochondria [18;27]. In our experiments, repression of Complex 
V components, particularly ATP5α1, a subunit of the ATP synthase complex, may be responsible 
for the mitochondrial dysfunction resulting from disruption of AHR signaling, since AHR can 
directly interact with ATP5α1 and modulate mitochondrial function [42]. Ultimately, 
mitochondrial dysfunction from AHR disruption in utero results in ultrastructural alterations 
suggestive of mitochondrial stress and degeneration, and also increased mitochondria abundance 
within the heart, most likely as a compensatory effect for the loss of efficiency of individual 
mitochondria.  
Altogether, our observations strongly indicate that developmental disruption of AHR 
function causes covert cardiac morphological and functional effects due to, or accompanied by, 
many dysregulated signaling pathways involved in cardiogenesis, cardiac function, and 
metabolism, which, collectively, are likely to impair postnatal cardiovascular function.  Whether 
embryonic disruption of AHR pathways results in adult cardiac insufficiency is yet to be 
determined. The results presented here provide strong evidence in support of a central role for the 
AHR signaling network in heart development, where the AHR is also a target of environmental 
agents that can cause departure from homeostasis and underlie congenital heart disease. These 
findings underscore the AHR as a key contributor to heart development and homeostasis and 
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Figure 1 AHR localization during early heart formation in Ahr+/+ mice is significantly reduced 
by TCDD exposure - (A) Five-micron-thick sections of embryonic mouse hearts collected at E13.5, 
E15.5, and E18.5 from Ahr+/+, naïve or exposed to AHR ligand (TCDD) in utero, were used for 
immunofluorescent detection of AHR (red) and cardiac troponin T (green). Staining with DAPI 
identifies the nuclei. AHR – aryl hydrocarbon receptor, cTnT – cardiac troponin T, DAPI – nuclei, 
scale bar = 50 µm. (B) Quantification of nuclear localization of AHR (AHR Index) at the indicated 
embryonic developmental times. The AHR index is shown as the mean percent positive nuclei ± 




Figure 2 Structural changes in the developing myocardium induced by AHR disruption - (A) 
Sections from the same embryos used in Fig. 1 were used for histomorphometric assessment of 
the developing myocardium. Arrowheads point to the left ventricle walls. H&E stain is shown. 
Scale bar = 500 µm. (B, C) Quantification of histomorphometric ventricular measurements at the 
indicated embryonic developmental times. Shown is the mean ± SEM; * p≤0.05. (D) Embryo heart 
wet weights relative to body weight at the indicated embryonic developmental times, shown as the 
percent of mean total body weight ± SEM; * p≤0.05. (E) Sections from the same embryos used in 
Fig. 1 were used for immunohistochemical detection of Ki-67 as a proxy for cellular proliferation 
(golden-brown nuclei - arrow) and counterstained with Harris hematoxylin. Scale bar = 50 µm. (F) 
Quantification of nuclear localization of Ki-67 (Proliferation Index) at the indicated embryonic 
developmental times. The proliferation index is shown as the mean percent positive nuclei ± SEM; 





Figure 3 Effect of developmental AHR disruption on embryonic heart function - Ahr+/+ embryos, 
naïve (blue) or exposed to ligand (red) in utero, and Ahr-/- embryos (green) were subjected to in 
utero echocardiography at E15.5 to assess heart rate (A), ventricular diameters (B), right ventricle 
stroke volume (C), left ventricle stroke volume (D), ventricular ejection fraction (D), right 
ventricle diastolic and systolic wall thickness (E), and left ventricle diastolic and systolic wall 






Figure 4 AHR signaling networks involved in cardiogenesis and cardiac homeostasis – (A) The 
fraction of genes significantly altered in the right atrium of both Ahr-/- and TCDD-exposed Ahr+/+ 
mice (yellow bars) or either solely Ahr-/- (red bars) or solely TCDD-exposed Ahr+/+ (blue bars) 
mice is shown for genes in each of the ontogeny pathways indicated in the abscissa. The green 
diamonds indicate the percent of genes that are in common between Ahr-/- and TCDD-exposed 
Ahr+/+ conditions. Red and blue stars represent the –log(p-value), as a measure of the significance 
of the observation. (B) Same analysis as in (A) for the results with the ventricles. (C) Selected list 
from genes in section (A) of highly concordant genes from Ahr-/- and ligand-exposed Ahr+/+ 
embryo hearts with critical roles in cardiogenesis, and congenital heart disease. (D) Differentially-
expressed Ingenuity® IPA networks comparison between Ahr-/- embryo hearts (light blue) and 
ligand-exposed Ahr+/+ (dark blue). The vertical red line marks the threshold of statistical 





Figure 5 AHR regulates NKX2-5 expression in the developing heart - (A) Higher digital 
magnification of embryonic left atrium collected at E15.5 from Ahr-/- mice and Ahr+/+ mice either 
naïve or exposed to TCDD in utero, used for immunohistochemical detection of NKX2-5 (DAB-
positive nucleus shown by red arrow in inset, negative nucleus shown by green arrow) and 
counterstained with Harris hematoxylin. (B) Quantification of NKX2-5-positive nuclei at the 
indicated embryonic developmental times. The NKX2-5 index is shown as the mean percent 






Figure 6 Disruption of AHR signaling perturbs the regulation of molecular networks that 
control mitochondrial function during development - Fold change in expression of significantly 
altered genes in (A) functional mitochondrial pathways; (B) oxidative phosphorylation (B), and 





Figure 7 Disruption of AHR signaling induces changes in mitochondrial abundance and 
structure - (A) Quantification of heart mitochondrial DNA relative to nuclear DNA, defined as 
the ratio of mtDNA to nDNA, at E13.5, E15.5 and E18.5 and expressed as the mean fold change 
relative to naïve Ahr+/+ hearts ± SEM; * p≤0.05. (B) Ultra-thin sections of embryonic hearts 
collected at E13.5, E15.5, and E18.5 from Ahr-/- and Ahr+/+, either naïve or exposed to ligand in 
utero, were used for transmission electron microscopy evaluation of the cardiomyocyte 
ultrastructure. Representative photomicrographs illustrating higher density of mitochondria 
(arrowheads) within the embryonic cardiomyocyte sarcoplasm in Ahr-/- embryos and in ligand-
exposed Ahr+/+ compared to naïve Ahr+/+ embryos. Individual or clusters of mitochondria showed 
ultrastructural features of stress and degeneration (arrows), as evidenced by focal to global 
swelling, loss of matrix density, as well as cristae unpacking, disorganization and cristolysis, 
affecting a higher number of mitochondria in AHR ligand-exposed Ahr+/+ hearts. Uranyl acetate 
and lead citrate stain. Scale bar = 500 nm.  
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1. Supplemental Materials and Methods  
a. Animals and Treatments 
All experiments were conducted using the highest standards of humane care in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals and were approved in advance 
by the University of Cincinnati Institutional Animal Care and Use Committee. C57BL/6J mice 
used in these experiments were originally purchased from the The Jackson Laboratory (Bar 
Harbor, ME) and thereafter maintained in our colony. C57BL/6J mice were housed in a pathogen-
free animal facility under a standard 12-hour light/12-hour dark cycle with ad libitum water and 
chow. The original Ahr-/- breeding stock had been crossed for 7 generations onto a C57BL/6J 
background at The Jackson Laboratory and thereafter maintained in our laboratory on the same 
background (for about 14 years). On embryonic day (E) 7.5 pregnant Ahr+/+ dams were treated by 
oral gavage with either corn oil (vehicle) or with TCDD (0.1, 0.5, 1, 2.5, 5, or 50 μg/kg of maternal 
weight) in corn oil vehicle, which was repeated on embryo days E9.5 and E11.5; Ahr-/- pregnant 
dams remained untreated throughout gestation. TCDD doses were specifically selected to include 
environmentally-relevant ranges, and are within range of the reported mean human background 
body burdens for dioxin and dioxin-like compounds (PCDDs/PCDFs/PCBS) of approximately 9–
13 ng TEQ/kg  (DeVito et al. 1995). 
b. Histology, Immunohistochemistry, and Microscopy 
Following euthanasia, the uteri were harvested into chilled phosphate buffered saline 
(PBS), pH 7.4. The number of embryos was counted, and each embryo was dissected, blotted, and 
weighed. Following weight determination, each embryo was sectioned transversally at the level of 
the diaphragm for optimal fixation, and the upper torso was immersed in 4% freshly-prepared 
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paraformaldehyde (pH 7.4) at 4°C for 24 hrs. Histological sections of the embryonic hearts were 
obtained by transverse serial sectioning of the entire embryonic thorax.  Sections were collected 
onto charged glass slides (Superfrost Plus, Fisher Scientific).  
For immunohistochemistry, polyclonal primary antibodies against AHR (anti-rabbit, SA-
210 Enzo), NKX2-5 (anti-rabbit, Ab35842, Abcam), and Ki-67 (anti-rabbit, Millipore) were used 
at 1:200, 1:100, and 1:200 dilutions, respectively. The primary antibodies were probed with either 
a DAB kit (ImmunoCruz rabbit ABC Staining System, Santa Cruz), following manufacturer’s 
instructions, or fluorescently labeled secondary antibodies (AlexaFluor 488/594/680, Life 
Technologies) at 1:1000 dilutions. Primary antibodies were incubated overnight at 4°C. For DAB 
stains the sections were counter-stained with Harris hematoxylin (Sigma-Aldrich) as 
recommended by the DAB kit manufacturer, while for fluorescence analyses the nuclei were 
identified with DAPI present in the cover slip mounting medium (Vector Labs®). Macroscopic 
examinations and images were obtained using a dissection microscope (Leica MZ16FA equipped 
with a DFC4802 camera and Leica Application Suite).  
Histomorphometry and microscopic images were obtained with a bright field microscope 
(Zeiss Axio Scope.A1) equipped with an AxioCam ERc5s and the Zen Blue Edition suite (Zeiss). 
Masson’s trichrome histochemistry was performed as instructed by the manufacturer (ScyTek 
Laboratories). Quantification of fibrosis on Masson’s trichrome-stained sections imaged using the 
40x objective was performed as described elsewhere (Teekakirikul et al. 2010).  Immunostaining 
quantification was performed using the color deconvolution plugin and threshold functions of the 
ImageJ 1.47h (National Institutes of Health) on 15 non-overlapping high power field (40x 
objective) images per embryo (encompassing right and left atria, right and left ventricles, and 
interventricular septum). These images were used to determine the number of labeled nuclei versus 
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the total number of nuclei, which was later factored in to yield the percentage of nuclei labeled (% 
positive index).  
c. RNA.seq analysis 
Following euthanasia of the dam, the uteri were immediately harvested and rinsed with 
sterile chilled PBS and blotted dry. Embryos were dissected from the uterus and immediately 
transferred into RNA-Later (Ambion) where the hearts were excised. Each heart was 
microdissected into right atrium, left atrium, and ventricles with the assistance of a dissecting 
microscope. Individual samples were stored in 200 µL of RNA-Later at -80°C until RNA 
extraction. Total RNA was extracted with the RNeasy Mini Kit with Proteinase K and DNAse 
steps (QIAGEN).  
All steps of library construction, cluster generation, and HiSeq (Illumina) sequencing were 
performed with triplicate samples by the Genomics Sequencing Core of the Department of 
Environmental Health, University of Cincinnati. Library construction was done with the TruSeq 
RNA sample preparation kit (Illumina) using 1 μg of total RNA, with RNA integrity number ≥ 7.0 
as determined with an Agilent 2100 Bioanalyzer (Agilent Technologies) to purify poly-A–
containing mRNA with oligo-dT–attached magnetic beads. The purified mRNA was 
enzymatically fragmented, with random hexamers primed for first and second strand cDNA 
synthesis, followed by purification using Agencourt AMPure XP beads (Beckman Coulter). 
Overhangs in the double-stranded cDNA were blunt-ended by end repair and adenylated with a 
single A-nucleotide at the 3´ end to prevent self-ligation in the following ligation step. AMPure 
XP bead-purified fragments were ligated to sample-specific indexing adapters and enriched by 10 
cycles of PCR using adapter-specific primers. A 1-μL aliquot of purified PCR product (from a 
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total sequencing library of 30 μL) was analyzed in an Agilent bioanalyzer using a DNA 1000 chip 
to check DNA size (~ 260 bp) and yield. To quantify the library concentration for clustering, the 
library was diluted 1:100 in a buffer containing 10 mM Tris-HCl, pH 8.0, and 0.05% Tween 20, 
and analyzed by quantitative PCR (qPCR) with a KAPA Library Quantification kit 
(KapaBiosystems) using an ABI 9700HT real-time PCR machine (Applied Biosystems). Equal 
amounts of six individually indexed cDNA libraries were pooled for clustering in an Illumina cBot 
system flow cell at a concentration of 8 pM using Illumina’s TruSeq SR Cluster Kit v3, and 
sequenced for 50 cycles using a TruSeq SBS kit on the Illumina HiSeq system. Each sample 
generated approximately 30 million sequence reads. Sequence reads were demultiplexed and 
exported to fastq files using CASAVA 1.8 software (Illumina). The reads were then aligned to the 
reference genome (mm10) using TopHat aligner. The counts of reads aligning to each gene’s 
coding region were summarized using ShortRead and associated Bioconductor packages 
(GenomicFeatures, IRanges, GenomicRanges, Biostrings, Rsamtools) for manipulating and 
analysis of next-generation sequencing data and custom-written R programs. 
Differential gene expression analysis between Ahr+/+ and Ahr-/- embryos or between AHR 
ligand-exposed and naïve Ahr+/+ embryos was performed separately at each of the three different 
developmental time points (E13.5, E15.5, and E18.5). Statistical analyses were performed to 
identify differentially expressed genes for each comparison using the negative-binomial model of 
read counts as implemented in the Bioconductor DESeq package. Significant genes were selected 
based on a false-discovery rate–adjusted p-value < 0.0001. We analyzed the RNA.seq data using 
Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, http://www.ingenuity.com). 
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d. Embryo (in utero) echocardiography 
At the gestation day corresponding to embryonic day (E) 15.5, three naïve (vehicle) Ahr+/+, 
five AHR ligand exposed Ahr-+/+, and five Ahr-/- pregnant dams were lightly sedated with isoflurane 
anesthesia on a heated pad, and their lower abdomens were shaved. In order to avoid imaging the 
same embryo twice, the probe was placed on the far lower right flank of the abdomen and 
mechanically transitioned caudal to cranial while stopping to obtain B-mode (bright 2D image), 
M-mode (motion mode), color and Doppler images of each embryo’s cardiac structure; the process 
was then repeated identically on the left side. Embryonic orientation, in order to determine right 
and left ventricle, was confirmed via scanning from top to bottom of each embryo and by using 
abdominal organs’ laterality. The in utero echocardiographic data were averaged for all the 
embryos in a litter and analyzed as the mean ± SEM of the litters.  
2. Supplemental Results 
a. Experimental design and gestational outcomes 
The experimental design, including the activation of AHR by ligand (TCDD) exposure, is 
illustrated in Supplemental Fig. 1A. Gestational AHR agonist exposure resulted in significant 
embryo body weight increase at E18.5 (wet and dry weights), while a decrease in body weight (dry 
only) was observed at E18.5 with AHR receptor ablation (Supplemental Fig. S1B and S1C). 
Maternal and embryonic liver weights were measured as a proxy for ligand exposure, since 
accumulation and increase in liver weight is a well-documented effect of AHR agonist exposure 
(Besteman et al. 2007; Weinstein et al. 2008). Gestational AHR agonist exposure resulted in 
significant dose-dependent increases in liver weights in both dams (Supplemental Fig. S1D) and 
embryos (Supplemental Fig. S1E and S1F), corroborating embryo exposure to the AHR agonist. 
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In contrast, Ahr-/- dam livers were significantly smaller than naïve Ahr-+/+ dam livers, in agreement 
with the documented highly-penetrant portosystemic shunting phenotype associated with 
constitutive deletion of the AHR (Lahvis et al. 2000). AHR agonist exposure at the highest dose 
(i.e. 50 µg/kg) resulted in no statistically significant changes to maternal heart, spleen, or kidney 
weights (data not shown). Using the described exposure design, exposures at doses of 2.5 µg/kg 
and higher resulted in 100% perinatal lethality, occurring mostly within 48 hours of birth 
(Supplemental Fig. S1G). No statistically significant reductions in the numbers of viable embryos 
(i.e., live at the time of sampling) were observed for either dose across time points, except for Ahr-
/- litters (Supplemental Fig. S1H) – the latter also being a documented effect of constitutive AHR 
ablation (Abbott et al. 1999). Macroscopic examination of embryos and stillbirths revealed a dose-
dependent increased incidence of palatoschisis (cleft palate), an established teratogenic effect of 
this specific AHR agonist (TCDD), in embryos from dams who received doses of 2.5 µg/kg or 
higher. Palatoschisis was interpreted to be one of the contributing factors for the observed perinatal 
mortality in exposures at doses of 2.5 µg/kg and higher, but not all decedent pups were affected. 
A subset of pups (N = 3 or more) from each treatment condition (up to and including the 1 µg/kg 
dose) was carried to PND 30 and subsequently necropsied to assess the occurrence of overt terata, 
such as hydronephrosis and palatoschisis.  None was observed upon gross examination (data not 
shown).    
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3. Supplemental Tables 
a. Supplemental Table S1 
 
Differentially-expressed genes in the right atrium of naïve Ahr-/- and ligand-exposed Ahr+/+ 
embryos at E15.5. Magnitude of change (log ratio) and p-values are color-coded from lower (blue) 
to higher (red) values.  
  
log ratio p-value log ratio p-value
Hand1 -2.5758 7.23E-12 Myl2 -2.9375 4.03E-40
Myl2 -2.3784 1.36E-25 Irx4 -2.134 3.07E-32
Irx4 -2.285 8.35E-38 Hopx -2.0144 2.61E-35
Hey2 -1.8987 1.09E-27 Hand1 -2.006 7.37E-08
Bves -1.8381 3.48E-33 Mycn -1.666 1.04E-15
Mycn -1.6946 2.34E-16 Hey2 -1.5173 9.98E-19
Hopx -1.6742 1.09E-28 Bves -1.5016 1.13E-22
Gja1 -1.614 1.75E-28 Gja1 -1.2953 1.15E-18
Dio2 -1.5157 0.00019 Cited1 -1.0917 6.14E-06
Cited1 -1.2072 5.04E-11 Dio2 -0.8163 0.00628
Apln -0.8293 0.00117 Apln -0.6513 0.00983
Hdac1 0.414 0.0105 Hdac1 0.42008 0.01231
Smarca4 0.54283 0.01004 Smarca4 0.44926 0.00316
Myc 0.76267 0.01689 Smarca2 0.76184 0.00033
Smarca2 0.90388 3.21E-07 Nr2f2 0.97183 0.00019
Gata2 1.04024 0.00051 Myc 1.0391 9.00E-06
Tcf7l1 1.04887 0.0004 Tbx5 1.14632 4.25E-07
Foxc1 1.15313 0.00019 Gata2 1.16332 0.00088
Nppa 1.20529 9.57E-17 Tcf7l1 1.25224 3.58E-09
Tbx5 1.35936 3.59E-15 Gata3 1.29114 0.00742
Nr2f2 1.58927 1.98E-17 Foxc1 1.29823 2.09E-08
Foxc2 1.74901 3.82E-05 Tbx2 1.40012 1.07E-05
Rarg 2.02173 7.08E-07 Rarg 1.44205 1.67E-05
Gata3 2.04706 1.20E-09 Nppa 1.65797 0.00218
Shox2 2.19626 0.00187 Foxc2 2.13984 3.36E-09
Tbx2 2.41087 1.46E-05 Shox2 2.69182 3.94E-18
Isl1 4.09134 1.58E-10 Hoxa3 2.7783 0.0006
Hoxa3 4.15614 1.96E-09 Isl1 2.93557 1.61E-08


















b. Supplemental Table S2 
 
Comparative analysis of the differentially-expressed genes in the right atrium of naïve Ahr-/- 
and ligand-exposed Ahr+/+ embryos at E15.5 with the previously published cardiac transcriptome 
of Nkx2-5 mutant mice (Prall et al. 2007).  Similarities in identity and direction of change are 
highlighted in yellow.  
  
Nkx2-5 mutant gene expression
(Prall et al 2007)
Ahr+/+ + TCDD Naïve Ahr-/-
Downregulated Direction Agrees Nkx2-5 mutant Direction Agrees Nkx2-5 mutant
Ankrd1 up no unchanged no
Nppb (Bnp) down yes down yes
Nr2f2 (coup TFII) up no up no
Myl2 down yes down yes
Irx4 down yes down yes
Smpx (Chisel) unchanged no down yes
Nppa (Anf) up no up no
Wnt11 up no up no
Upregulated
IGFBP5 up yes up yes
Pdgfra up yes up yes
Tnc up yes up yes
Isl1 up yes up yes
Tbx5 up yes up yes
Bmp2 unchanged no unchanged no
Fgf10 up yes up yes
Hhex unchanged no unchanged no
Unaltered
Cer1 unchanged yes unchanged yes
Dan unchanged yes unchanged yes
NOG unchanged yes unchanged yes
Bmp4 up no up no
Bmp7 down no down no
Dkk1 unchanged yes unchanged yes
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4. Supplemental Figures 
 
a. Supplemental Figure S1 - (A) Experimental design for gestational exposure to the prototypical 
AHR ligand (TCDD). (B) Whole embryo wet weight (grams) from naïve Ahr+/+, ligand-
exposed Ahr+/+, and Ahr-/- embryos at the indicated developmental time points. Mean ± SEM; 
* p≤0.05. (C) Whole embryo dry weight (grams) from naïve Ahr+/+, ligand-exposed Ahr+/+, 
and Ahr-/- embryos at the indicated developmental time points. Mean ± SEM; * p≤0.05. (D) 
Maternal body weight (grams) from naïve Ahr+/+dams, Ahr+/+dams exposed to 5 or 50 µg/kg 
of AHR ligand (TCDD), and Ahr-/- dams. Mean ± SEM; * p≤0.05. (E) Maternal liver weight 
(expressed as the percent of body weight) from naïve Ahr+/+dams, Ahr+/+dams exposed to 5 
µg/kg or 50 µg/kg of AHR ligand (TCDD), and Ahr-/- dams. Mean ± SEM; * p≤0.05. (F) Fetal 
liver weight (expressed as the percent of body weight) from naïve Ahr+/+, ligand-exposed 
Ahr+/+, and Ahr-/- embryos at the indicated developmental timepoints. Mean ± SEM; * p≤0.05. 
(G) Representative macroscopic illustration of AHR ligand-induced fetal liver enlargement. 
Scale bar = 1mm. (H) Pup viability (i.e. pups alive at 24 hours postpartum) from naïve 
Ahr+/+dams, Ahr+/+dams exposed to 0.1, 5, or 50 µg/kg of AHR ligand (TCDD), and Ahr-/- 
dams. Mean ± SEM; * p≤0.05. (I) Embryo viability (i.e., live embryos at E13.5, E15.5 or E18.5) 
from naïve Ahr+/+dams, Ahr+/+dams exposed to 5 or 50 µg/kg of AHR ligand (TCDD), and 
Ahr-/- dams. Mean ± SEM; * p≤0.05. (J) Representative macroscopic illustration of embryo 
hearts from naïve Ahr+/+, ligand-exposed Ahr+/+, and Ahr-/- embryos at E13.5, E15.5, and E18.5. 




b. Supplemental Figure S2 – Annotated representative in utero echocardiography illustrations at 








c. Supplemental Figure S3 - Five-micron-thick sections of embryonic hearts collected at E13.5 
from Ahr+/+ embryos, naïve or exposed to AHR ligand (TCDD) in utero, were used for 
immunofluorescent detection of AHR (red) and cardiac troponin T (green). Staining with DAPI 
identifies the nuclei. AHR – aryl hydrocarbon receptor, cTnT – cardiac troponin T, DAPI – 





d. Supplemental Figure S4 - One-micron-thick sections of embryonic hearts collected at E13.5, 
E15.5, and E18.5 from Ahr+/+ hearts, naïve or exposed to AHR ligand (TCDD) in utero, and 
Ahr-/- hearts were used for histomorphometric assessment of the developing myocardium. The 




e. Supplemental Figure S5 - (A) Experimental design for RNA.seq experiment and analyses. 
RNA sequencing of naïve Ahr+/+, Ahr-/-, and ligand-exposed Ahr+/+ embryonic hearts. Hearts 
were microdissected into right atrium, left atrium, and ventricles, at the three distinct 
developmental milestones in cardiogenesis (E13.5, E15.5, and E18.5). An example comparison 
for the E13.5 heart and right atrium compartment is shown. (B) Differentially expressed genes 
from naïve Ahr+/+, ligand-exposed Ahr+/+, and Ahr-/- embryo hearts at the indicated 




f. Supplemental Figure S6 - Venn diagrams illustrating the number of common differentially-
expressed genes in the right atrium at E15.5 of Ahr-/- and ligand-exposed Ahr+/+ embryonic 





g. Supplemental Figure S7 - Differentially-expressed Ingenuity® IPA’s networks for various 




h. Supplemental Figure S8 - (A) Five-micron-thick sections of embryonic hearts collected at 
E13.5, E15.5, and E18.5 across subanatomical areas (RA, right atrium; LA, left atrium; RV, 
right ventricle; IVS, interventricular septum; LV, left ventricle) from Ahr-/- embryos and Ahr+/+ 
embryos either naïve or exposed to TCDD in utero, were used for immunohistochemical 





i. Supplemental Figure S9 - Ingenuity® IPA Mitochondrial Dysfunction Pathway status at E.15.5 
in the right atrium of ligand-exposed Ahr+/+ embryo hearts relative to naïve Ahr+/+ embryo 
hearts. Magenta lines indicate nodes with differentially-expressed genes. Shades of green 
indicate downregulation, while shades of red indicate upregulation; blank nodes indicate no 





j. Supplemental Figure S10 - Ingenuity® IPA Mitochondrial Dysfunction Pathway status at 
E.15.5 in the right atrium of ligand-exposed Ahr-/- embryo hearts relative to naïve Ahr+/+ 
embryo hearts. Magenta lines indicate nodes with differentially-expressed genes. Shades of 
green indicate downregulation while shades of red indicate upregulation; blank nodes indicate 
no differential expression.   
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The Developmental Origins of Health and Disease (DOHaD) Theory proposes that the 
environment encountered during fetal life and infancy permanently shapes tissue physiology and 
homeostasis such that damage resulting from maternal stress, poor nutrition, and/or exposure to 
environmental agents may be at the heart of adult-onset disease. In this context, we have shown 
that interference with endogenous developmental functions of the aryl hydrocarbon receptor 
(AHR), either by gene ablation or by exposure in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), a potent AHR ligand, causes structural, molecular, and functional cardiac abnormalities 
and altered heart physiology in mouse embryos. To test if, in accordance with the DOHaD Theory, 
these embryonic effects progress to yield an adult phenotype, we investigated whether AHR 
signaling disruption by Ahr ablation or TCDD exposure in utero resulted in cardiac abnormalities 
in adult mice. Ten-month-old adult Ahr-/- and TCDD-exposed Ahr+/+ mice showed a sexually and 
genetically dimorphic abnormal cardiovascular phenotype characterized by echocardiographic 
findings of hypertrophy, ventricular dilation, and increases in heart weight, resting heart rate, and 
systolic and mean blood pressure, as well as decreased exercise tolerance. In association with these 
effects, genes in signaling networks related to cardiac hypertrophy and mitochondrial function 
were differentially expressed. Cardiac dysfunction in mouse embryos resulting from in utero AHR 
signaling disruption seems to persist and progress into abnormal cardiac structure and function, 
ultimately predisposing the adult to cardiac disease late in life. These findings underscore the 
conclusion that AHR signaling in the developing heart is a critical target of environmental factors 





Congenital heart disease (CHD) is the most common type of birth defect worldwide, 
encompassing 25–30% of all cases of malformations [1], and a major cause of adult cardiovascular 
morbidity and insufficiency [2–4]. Even so, the precise etiological factors underlying CHD 
incidence remain largely unknown [5,6]. Mutations in specific genes, such as homeobox 
transcription factors that govern the early events of cardiogenesis and heart development, have 
been associated with CHD and adult cardiovascular disease in humans and mice [7–12]. In 
contrast, non-Mendelian CHD is multifactorial and most likely the product of genetic and 
environmental interplay [5]. A recent review of 3,772 CHD cases reported that only 11% of the 
patients had a genetic defect [6], underscoring that the etiology of the greater portion of CHD cases 
is undetermined and possibly owing to gene-environment interactions. It is increasingly 
recognized that gene-environment interactions exert their highest impact during development [13–
16]. This concept is in agreement with the theory of the Developmental Origins of Health and 
Disease (DOHaD), which proposes that the environment encountered by a developing organism 
during conception, embryonic life, infancy, and early adulthood permanently changes the 
structure, function and/or metabolism, ultimately shaping the long-term control of tissue 
physiology and homeostasis [17,18]. Consequently, investigating how environmental insults 
during the embryonic and fetal periods may result in congenital and adult onset cardiac disease is 
crucial to understanding the etiology of the vast majority of CHD cases. 
The aryl hydrocarbon (Ah) receptor (AHR) is a ligand-activated transcription factor and a 
member of the basic-region-helix-loop-helix PER/ARNT/SIM (bHLH-PAS) superfamily [15]. 
The various members of this family function as environmental sensors [19] and differentially 
regulate signaling pathways related to development and homeostasis in many organs [20]. 
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Xenobiotic environmental ligands of the AHR have been shown to adversely affect the 
cardiovascular system in experimental models in vitro [21,22] and in vivo [14,15,23–27]. 
Specifically, the AHR has been linked to cardiovascular health and disease through an endogenous 
signaling pathway participating in a complex regulatory target network for cardiogenesis and 
cardiovascular homeostasis [22,27], with enduring functions in postnatal cardiac physiology, such 
as regulating cardiac sufficiency and blood pressure [28–30] as well as inducing cardiovascular 
pathology [31]. 
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin; dioxin) is the prototypical and most potent 
AHR exogenous ligand [32].  This molecule off-competes endogenous ligands, diverting the 
receptor from its physiological functions [33]. In parallel, proteasome-dependent degradation of 
ligand-activated Ah receptor results in “post-exposure AHR down-regulation”, which, at least 
temporarily, recapitulates an AHR-null condition [34,35]. The combinatorial product of AHR 
down-regulation and misappropriation, via constitutive or exogenous ligand-induced AHR 
disruption, has been shown to dysregulate several biological processes, such as immune 
responsiveness, growth factor signaling, cell proliferation, cell differentiation, cell cycle arrest, 
and apoptosis [14,36–38], as well as cardiogenesis and cardiovascular homeostasis [27].  
The effect of in utero AHR disruption during early life (specifically embryonic days [E] 
E13.5, E15.5, and E18.5) is evident as covert cardiac morphological and functional effects, 
accompanied by many dysregulated signaling pathways involved in cardiogenesis, cardiac 
function, and mitochondrial function [27]. These findings build on previous in vitro evidence 
showing that activation, inhibition, or knockdown of Ahr during mouse embryonic stem (ES) cell 
differentiation all significantly inhibit the formation of contractile cardiomyocyte nodes [22]. 
Taken together, these data suggest that both in vitro and in vivo AHR disruption-related effects 
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have the potential to impair postnatal cardiovascular maturation and function, in a fashion 
analogous to the adult cardiac insufficiency resulting from CHD in humans. To address the 
hypothesis that an altered adult cardiovascular structure and function can be experimentally linked 
to gestational disruption of the AHR signaling pathway in vivo, we studied the molecular, 
structural, ultrastructural, and functional cardiac phenotypes of adult naïve Ahr knockout mice 
(Ahr-/-) or wild-type (Ahr+/+) adult mice that were exposed in utero to TCDD or to vehicle. Our 
data show that abnormalities induced by AHR disruption in utero persist long after clearance of 
the inducing agent and thus have a significant effect on predisposing the adult to cardiac disease. 
Similar to human CHD, the congenital heart defects induced by AHR disruption in mouse embryos 
appear to be a major cause of cardiac insufficiency in the adult. 
3. Materials and Methods 
3.1. Animals and Treatments 
All experiments were conducted using the highest standards of humane care in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals and were approved in advance 
by the University of Cincinnati Institutional Animal Care and Use Committee. At least three age-
matched Ahr+/+ and three Ahr-/- C57BL/6J female mice were mated overnight with Ahr+/+ and Ahr-
/- C57BL/6J male mice, respectively. Maternal gestational exposure to the prototypical AHR ligand 
TCDD was performed via oral gavage at key developmental time points as previously described 
[22,27], and as illustrated in detail in Supplemental Fig. S1A. Briefly, Ahr+/+ dams were treated by 
oral gavage on E7.5, E9.5 and E11.5 with either corn oil (vehicle) or with TCDD at doses of 0.1 
or 1 μg/kg (hereafter referred to as low-dose and high-dose, respectively), which based on previous 
determinations are estimated to produce tissue levels of 0.034 ng and 0.34 ng, respectively, per 
whole embryo [39]. TCDD doses were specifically selected to include environmentally-relevant 
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levels of contamination and are within range of the reported mean human background body 
burdens for dioxin and dioxin-like compounds (PCDDs/PCDFs/PCBS) of approximately 9–13 ng 
toxic equivalents (TEQ)/kg [40]. Mice were weaned on postnatal day (PND) 21, and males and 
females were kept separately in standard housing conditions until the scheduled necropsy at PND 
300 (= 10 months of age).  
3.2. Heart samples 
Following euthanasia by carbon monoxide asphyxiation, hearts were immediately 
harvested, rinsed briefly in PBS (pH 7.4) to dislodge blood, gently blotted to remove excess fluids, 
and weighed using a high definition scale. Organ weights were normalized to body weight. Hearts 
were longitudinally bisected with one half used for morphological studies (i.e., routine histological 
processing) and the other half processed for molecular studies (RNA.seq and western blot analysis) 
as detailed below.  
3.3. Histology and Microscopy 
Tissues samples were fixed for 48 hours in freshly-prepared 4% paraformaldehyde (pH 
7.4) at 4°C (Sigma-Aldrich), rinsed in serial ethanol dilutions, and then routinely processed for 
histology. Paraffin sections were stained with hematoxylin and eosin (H&E) using standard 
protocols. Masson’s Trichrome (MT) histochemical staining (ScyTek Laboratories, Inc.) and 
wheat germ agglutinin (WGA) Texas Red®-X Conjugate staining (Life Technologies) were 
performed according to the manufacturer’s instructions. Slides were visualized and imaged with 
an Axio Scope.A1 microscope equipped with an AxioCam ERc5s camera (Carl Zeiss 
Microscopy). MT analyses were performed on three hearts per sex from at least three litters, and 
experimental condition and MT-positive quantification was performed using the color 
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deconvolution plugin and threshold functions of ImageJ 1.47h software (National Institutes of 
Health) to determine the percentage of MT-positive tissue (% positive index). WGA analyses were 
performed using the manual contour function of the Zeiss’ Zen software (Zeiss Microscopy) to 
determine the mean cross-sectional myofiber area on at least 20 cross-sectioned myofibers in five 
non-overlapping high power fields (40x objective) of at least three hearts per sex and experimental 
condition.  
3.4. Transmission electron microscopy  
Microdissected samples from at least three freshly-harvested adult hearts per sex and 
experimental condition were immediately fixed in phosphate-buffered 3% glutaraldehyde (pH 7.4) 
at 4°C for 24 hours and submitted to the Pathology Research Core at Cincinnati Children’s 
Hospital Medical Center for sample processing and sectioning for electron microscopic 
examination. Samples were washed three times in 0.1 M cacodylate buffer (pH 4.4) and post-fixed 
in 1% osmium tetroxide buffered with 0.1 M cacodylate (pH 7.2) at 4°C for 1 h. After dehydration 
in serial alcohol and propylene oxide solutions, samples were infiltrated with and embedded in 
LX112. Thin sections were stained with 0.5% uranyl acetate and 3% lead citrate. Imaging was 
performed on a transmission electron microscope (7600; Hitachi). Five non-overlapping 
ultraphotomicrographs per grid were taken at 8000X, 25000X, and 70000X magnifications and 
further evaluated using Image J 1.47h (http://imagej.nih.gov/ij/) software.   
3.5. Mitochondria quantification  
Relative quantification of mitochondria in the adult hearts (ratio of mitochondrial DNA 
[mtDNA] to nuclear DNA [nDNA]) was carried out by real-time PCR as previously described 
[41]. Gene targets were the nuclear cytochrome P450 Cyp1a1 and the mitochondrial Nd5 
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(nicotinamide adenine dinucleotide dehydrogenase-5) genes. Primers for Cyp1a1 were: forward: 
5'- AGGCTCTTCTCACGCAACTC -3’; reverse: 5'- TAAGCCTGCTCCATCCTCTG -3’. 
Primers for Nd5 were: forward 5’-TGG ATG ATG GTA CGG ACG AA-3’; reverse 5’-TGC GGT 
TAT AGA GGA TTG CTT GT-3’.  
3.6. RNA.seq analysis 
Freshly-harvested adult hearts, from three mice per sex and experimental condition were 
microdissected into right atrium, left atrium, and ventricles. Individual samples were stored in 200 
µL of RNA-Later (Ambion), immediately frozen in liquid nitrogen, and further kept at -80°C until 
RNA extraction. Total RNA was extracted with the RNeasy Mini Kit (QIAGEN) with Proteinase 
K and DNAse steps. Additional methodology details for RNA.seq studies is provided in the 
Supplemental Materials and Methods. Briefly, all steps of library construction, cluster generation, 
and HiSeq (Illumina) sequencing were performed with triplicate samples by the Genomics, 
Epigenomics and Sequencing Core (GESC) in the University of Cincinnati. Sequence reads were 
aligned to the genome by using standard Illumina sequence analysis pipeline and further analyzed 
by the Statistical Genomics and Systems Biology core in the University of Cincinnati. Differential 
gene expression analyses between Ahr+/+ and Ahr-/- hearts or between AHR ligand-exposed and 
naïve Ahr+/+ hearts were performed separately for males and females. Statistical analyses were 
conducted to identify differentially expressed genes for each comparison using the negative-
binomial model of read counts as implemented in the Bioconductor DESeq package. Significant 
genes were selected based on a false-discovery rate–adjusted p-value < 0.0001. RNA.seq data was 




3.7. Western Blot Analysis 
Hearts from three mice per sex and experimental condition were removed, rinsed with PBS 
(pH 7.4), and rapidly frozen in liquid nitrogen. The preparation of total protein was performed by 
crushing the frozen hearts and placing the samples into lysis buffer (containing: 5% SDS, 50 mM 
Tris-HCl, pH 7.4, 250 mM Sucrose, 75 mM Urea, 10 mM DTT), protease inhibitor cocktail 
(Sigma, St. Louis, MO), and phosphatase inhibitor cocktail (Roche Indianapolis, IN). The samples 
were homogenized using a glass-Teflon homogenizer. Samples were then heated to 95ºC for 2 
minutes and centrifuged for 5 minutes at 10,000g, after which the supernatant was placed into a 
new tube and frozen at -80ºC. Total protein concentrations were determined using the BCA Protein 
Assay Kit (Pierce). Aliquots of total protein were separated on Novex gels (Life Technologies), 
transferred to nitrocellulose membranes (Life Technologies), and blocked with 5% milk-TBS-
Tween. Twenty µg of protein was loaded on 12% gels for the phospholamban antibodies: PLNt 
(Thermo Scientific), p-PLN S16 (Millipore) and p-PLN T17 (Badrilla). Fifty µg of protein was 
loaded on 4-12% gradient gels for the ryanodine receptor antibodies; RYR2a (Thermo Scientific), 
p-RYR S2808 (Badrilla) and p-RYR S2814 (gift of Dr. Arnold Schwartz, University of 
Cincinnati), or on a 10% gel for the Sodium/Calcium exchanger (NCX, Swant) and 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2, Thermo Scientific) immunoblots [42]. 
Protein bands were visualized using Western Lightning reagents (Perkin Elmer) and FluorChemE 
(ProteinSimple). The density of the bands was determined using AlphaEase software 
(ProteinSimple formally Alpha Innotech) and normalized to GAPDH for loading control. 
3.8. Echocardiography 
To evaluate for functional abnormalities, a full echocardiographic study was carried out as 
previously described [43] on three mice per sex and experimental condition starting at PND 60, 
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and repeated at PND 90, 150, and 270. Briefly, mice were anesthetized with isoflurane (1.5–2%), 
and images were obtained from a parasternal long axis view between 2 and 10 mm in depth in both 
M-mode and B-mode. Images were taken using the Vevo 2100 Ultrasound system equipped with 
a MS400 probe (30-MHz centerline frequency), and post-processed using a coded (blinded) 
strategy by an investigator at a separate workstation as previously described using the Vevostrain 
software (Visualsonic, Vevo 2100, v1.1.1 B1455). The B-mode, color and Doppler images were 
analyzed for valvular function and structural abnormalities, while the M-mode images were post-
processed for cardiac functional analysis including ventricular size, ejection fraction and cardiac 
output.  
3.9. Blood Pressure 
Blood pressure determinations (systolic and mean) were performed on three mice per sex 
and experimental condition at PND 270 by the tail-cuff method (Visitech Systems ® – Apex, 
NC/BP-2000 ® Blood Pressure Analysis) according to the manufacturer’s instructions. Briefly, 
mice were acclimatized to the equipment over the course of one week where no data was collected. 
In the subsequent week, determinations were carried out every other day for three days. For every 
session, 20 determinations were made. The data collected for each mouse was averaged per session 
and again per sex and group; the reported mean systolic and mean blood pressure per sex and 
group is the average of all three sessions.  
3.10. Exercise Tolerance 
Environmental cardiovascular challenge was performed by using an Accupacer Treadmill 
(Omnitech Electronics, Inc) and assessed at PND 60, 90, 150 and 270, using techniques adapted 
from previously described methods [44].  Briefly, mice were acclimatized to the equipment 
through three sham exercise sessions over the course of two weeks where no data was collected. 
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Each exercise session consisted of a warm up phase of five minutes at 10 m/s speed with no incline, 
followed by the endurance phase at 24 m/s speed and 6 degree incline for up to 60 minutes or until 
failure. Failure was defined as standing over the stimulus bars for more than five seconds, 
whereupon the mouse was removed from the treadmill. Time to failure was recorded individually 
and averaged per sex and experimental condition.  
3.11. Statistical Analyses 
Statistical analyses were done at each time point using unpaired two-tailed t-test of Ahr-/- or TCDD-
exposed Ahr+/+ mice relative to naïve Ahr+/+males or females, respectively.  
 
4. Results 
4.1. Developmental AHR disruption affects adult cardiovascular function. 
To determine whether disruption of AHR signaling in utero had long-lasting consequences 
to heart function and performance in adult mice, we examined echocardiographic endpoints of 
heart function, blood pressure, and exercise endurance capacity after forced treadmill exercise. 
Echocardiographic assessments revealed that Ahr-/- males and females had significantly increased 
left ventricle (LV) mass at 2 and 3 months of age, while Ahr-/- females had significantly increased 
LV mass also at 5 and 9 months of age. Increased LV mass was measurable both in absolute weight 
(Fig. 1A) and in weight normalized to body weight (Fig. 1B), while no significant effect was 
observed to body weight for any of the experimental groups (Supplemental Fig. S1B). Increased 
LV mass was accompanied by a pronounced increase in LV volume, suggesting the presence of 
LV dilation (Fig. 1C). In contrast, low- and high-dose TCDD-exposed Ahr+/+ males had 
significantly decreased LV mass (both absolute and normalized to body weight) at 5 and 9 months, 
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and decreased LV volume at 9 months. There were no correlative decreases in ejection fraction in 
any experimental group (Fig. 1D). In addition, a significant, albeit slight, increase of the aorta 
outflow diameter was noted in Ahr-/- males and females starting at 5 months and progressing at 9 
months (Supplemental Fig. S1C).   
Furthermore, at 10 months of age, Ahr+/+ males exposed to low- or high-dose TCDD had 
significantly increased resting (conscious) heart rates, approximately 8% and 13% higher, 
respectively, than naïve Ahr+/+ males, while Ahr-/- females had a significant 10% decrease in heart 
rate (Fig. 1E). In both Ahr+/+ males and Ahr+/+ females, exposure to low- or high-dose TCDD also 
caused a significant elevation of blood pressure, with increases in the range of 16 – 18% for males 
and 10 – 16% for females, at either TCDD dose and for both systolic (Fig. 1F) and mean 
(Supplemental Fig. S1D)  blood pressure.  
Exercise endurance, the time lapsed until mice stop running on a forced treadmill exercise 
protocol, significantly differed between naïve Ahr+/+ and Ahr-/- or TCDD-exposed Ahr+/+ mice. At 
all ages, Ahr-/- male and female mice significantly underperformed the endurance test in 
comparison to their Ahr+/+counterparts.  Ahr-/- males lasted 20 – 30% less than Ahr+/+ males, with 
a slight decrement of time at later time points. Ahr-/- females lasted 20 – 65% less than Ahr+/+ 
females, with a marked decrement of time at 5 and 7 months. At 3, 5, and 7 months, Ahr+/+ males 
exposed to high-dose TCDD lasted 35% less than naïve Ahr+/+ males. A similar decrement was 
observed at 7 months in Ahr+/+ males exposed to low-dose TCDD. Non-significant trends towards 
decreased endurance time were also noted at 7 months in Ahr+/+ females exposed to high-dose 
TCDD (Fig. 1G).  These results suggest that disruption of AHR signaling in utero has long-lasting 
consequences to heart function and performance in adult mice, evident when the adult mice are 
subjected to exercise endurance, an environmental stressor. 
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4.2. Developmental disruption of AHR signaling alters the structure of the adult 
myocardium.  
Exogenous ligand-driven or constitutive AHR signaling disruption during mouse heart 
development has been associated with molecular, structural, and functional effects to the fetal heart 
[27], but the extent to which these effects persist or progress in the adult heart has yet to be 
determined. To that end, we examined the structure and function of Ahr-/- and Ahr+/+ adult mice, 
with the latter exposed in utero to TCDD or unexposed. 
At 10 months of age, Ahr-/- males and females showed approximately 19% and 33%, 
respectively, significant increases in mean heart weight relative to body weight, while high-dose 
TCDD-exposed Ahr+/+ females had a significant 11% increase in mean heart weight relative to 
body weight (Fig. 2A). To further characterize the altered heart mass, we stained 5-µm-thick 
sections with fluorescently-labeled wheat germ agglutinin (Fig. 2B) to assess the morphometrical 
quantification of cross-sectional myofiber area. Heart weight increases in Ahr-/- males and females 
correlated with significant increases in mean myofiber cross-sectional area of 44% and 58%, 
respectively, while Ahr+/+ females exposed to high-dose TCDD had a 33% significant increase in 
mean myofiber cross-sectional area (Fig. 2C). In contrast, while the overall spread of individual 
myofiber areas was similar between naïve and TCDD-exposed Ahr+/+ males, high- and low-dose 
exposed Ahr+/+ males showed a significant loss of 24% and 13%, respectively, of myofiber cross-
sectional area, correlated to the observed lower heart weights. These findings suggest that the 
observed increased in heart weights of Ahr-/- males and females and high-dose TCDD-exposed 




Histological sections were stained with Masson’s trichrome (Fig. 2D) to assess myocardial 
remodeling by highlighting the differences in the amount of interstitial extracellular matrix, which 
were quantified as a proxy for myocardial fibrosis. Ahr-/- males and females had a significant, 
although small, increase in interstitial fibrosis, from about 0.1% positive sectional area in naïve 
Ahr+/+ males and females to about 1.25% and 0.75% in Ahr-/- male and female hearts, respectively 
(Fig. 2E). Ahr+/+ mice exposed to high-dose TCDD had a significant slight increase of about 0.4% 
and 0.3% in males and females, respectively. Altogether, these data suggest that disruption of AHR 
signaling in utero and its effects on the developing embryonic myocardium that we had previously 
observed [27] do in fact persist and affect myocardial structure in the adult. 
4.3. Disruption of AHR signaling during development has lasting effects in the adult heart 
transcriptome. 
A key question in the analysis of the role of gene-environment interactions in the 
developmental genesis of adult cardiac disease is whether interference with AHR endogenous 
functions, either by gene ablation or by exposure to TCDD in utero, causes persistent abnormalities 
detectable in both the embryo and the adult. In our previous work, we observed that a significant 
fraction of the mouse transcriptome, needed for attainment and maintenance of cardiac 
differentiation, was deregulated with striking similarity by both loss of the Ahr gene and exposure 
to TCDD in utero [27]. To search for genes that might be differentially expressed in the adult heart 
as a consequence of AHR disruption in utero, we used deep sequencing of the heart transcriptomes 
of Ahr-/- and TCDD-exposed Ahr+/+ mice, including right and left atrium, and ventricle tissue from 
males and females. Relative to naïve Ahr+/+ hearts, comparable numbers of genes were 
differentially-expressed in the right atrium of Ahr-/- males and females. The same was the case in 
Ahr+/+ males and females that had been exposed to high-dose TCDD in utero, and in the left atrium 
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and ventricles of Ahr-/- females. No significant gene numbers were found in the left atrium and 
ventricles of Ahr-/- males and low-dose TCDD-exposed Ahr+/+ males, and in the ventricles of high-
dose AHR ligand-exposed Ahr+/+ males, or right atrium of low-dose TCDD-exposed Ahr+/+ 
females (Fig. 2F). Curiously, sexually dimorphic quantitative differences were noted as female 
hearts tended to have an overall higher number of differentially-expressed genes in all 
experimental groups.  
To determine whether expression of specific genes affected in the embryo in our prior work, 
either at E13.5, E15.5, or E18.5 [27], persisted in the adult heart at 10 months of age, we carried 
out a comparison of the adult transcriptome to the transcriptome of embryonic hearts following 
AHR disruption in utero (following the design detailed in Supplemental Fig. S1E). The 
compartment-specific number of persistent genes, i.e., genes differentially expressed in the embryo 
heart and in the adult heart, is shown in Fig. 2G, while their respective identities are listed in 
Supplemental Table S1. The right atrium of Ahr-/- males and females and the left atrium of low-
dose TCDD-exposed Ahr+/+ females show the highest number of overlapping genes. Although no 
particular gene signature was noted, selected individual persistent genes are annotated to 
cardiovascular ontogenies, such as Col5a3, Nppa, and Wdr83, and mitochondrial function, such 
as Cox14 and Mrpl12.  
Comprehensive transcriptome analysis via the Ingenuity Pathway Analysis (IPA, Qiagen) 
platform revealed aberrant regulation of genes globally associated with cardiovascular disease 
together with individual genes associated with mitochondrial function. Genes important for 
maintaining cardiac structural homeostasis, contractility, promoters of cardiac hypertrophy, and 
regulating cardiomyocyte energy homeostasis had significantly altered expression in the AHR 
agonist-exposed Ahr+/+ female hearts, with an overall higher magnitude of change in high-dose 
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TCDD-exposed females (Fig. 3A). These changes were generally not observed in Ahr-/- hearts or 
in the hearts of Ahr+/+ males exposed to TCDD. Among the down-regulated pathways were IPA’s 
Toxicological Functions annotated to heart damage, function, and contractility. Up-regulated 
pathways included hypoxia signaling in the cardiovascular system, calcium signaling, 
mitochondrial dysfunction, oxidative stress response, and hormone nuclear receptor signaling.  
Analysis of upstream regulators identified potential genes predicted to contribute directly 
or indirectly to the observed aberrant regulation of these genes (Fig. 3B). Specific regulators 
included Hand2 (Heart and Neural Crest Derivatives Expressed 2) and miR-155. Hand2 has been 
identified as a key contributor to congenital heart disease [45] and was 2- to 2.5-fold decreased in 
expression in high- and low-dose TCDD-exposed Ahr+/+ female hearts.  Similarly, miR-155, 
recently associated with hypertrophic cardiomyopathy in humans [46], was decreased about 3-fold 
in high-dose TCDD-exposed Ahr+/+ female hearts. Also notably, expression of the cardiogenic 
transcription factor Nkx2-5 was significantly increased in the ventricles of Ahr-/- as well as low- 
and high-dose TCDD-exposed Ahr+/+ females (Fig. 4A) as previously reported in cardiac 
hypertrophy [47].  
In summary, disruption of AHR signaling during development yields lasting effects in the 
adult heart transcriptome, chiefly on networks related to cardiovascular homeostasis and function, 
with quantitative and qualitative differences between the atria and ventricles and with a 
predominance of effects in the adult female heart.   
4.4. Canonical calcium-handling mechanisms in the adult heart are preserved following 
AHR disruption in utero. 
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 To investigate whether calcium signaling had a role in the observed alterations of 
myocardial structure, we followed the expression of a selected panel of calcium-regulated genes 
and proteins involved in cardiac function and homeostasis known to change expression levels 
and/or phosphorylation status in heart disease, including Rcan1, Pln, Ryr2, Slc8a2, Slc8a3, Slc8a4, 
Atp2a1, and Atp2a2 [48]. Proteins included phosphorylated phospholamban (p-PLN) and total 
phospholamban (t-PLN), phosphorylated ryanodine receptor 2A (p-RyR2) and total 
phosphorylated ryanodine receptor 2A (t-RyR2), sodium-calcium exchanger (NCX), and the 
cardiac isoform of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2). A summary of the 
genes and proteins evaluated is included in Supplemental Table S2.   
In comparison to wild-type Ahr+/+ hearts, changes in the expression of Slc8a2, Ryr2, and 
Pln. Slc8a2 mRNA levels only showed a significant decrease in the ventricles of Ahr-/- females and 
Ahr+/+ females exposed to high-dose TCDD (Fig. 4B).  Expression of Ryr2 was lower in the left 
atrium and ventricles of Ahr+/+ males and females exposed to high-dose TCDD and in the left 
atrium of Ahr-/- females and Ahr+/+ females exposed to low-dose TCDD (Fig. 4C). Expression of 
Pln was lower in the ventricles of Ahr+/+ females exposed to high-dose TCDD (Fig. 4D). With 
regard to changes in protein levels, western blot analysis showed changes only in the levels of the 
sodium-calcium exchanger NCX, which increased expression by 9- and 6-fold in Ahr+/+ females 
exposed to high- or low-dose TCDD, respectively (Fig. 4E). All remaining trends in protein levels 
or phosphorylation status between naïve Ahr+/+ mice and other genotype or treatment conditions 
showed no significant differences (data not shown). The observed differentially expressed genes 
and protein data suggest that canonical calcium handling protein networks are largely preserved 
and, therefore, are not major contributors to the altered myocardial structure driven by AHR 
activation or loss-of-function. 
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4.5. Mitochondrial homeostasis in the adult heart is affected by developmental AHR 
disruption. 
  Mitochondrial dysfunction has been associated with AHR signaling disruption in vitro [49-
51] and in vivo [27,52–54], and extensively investigated as a key player in cardiovascular disease 
[55–57]. Of particular interest to this study, mitochondrial dysfunction with compensatory 
increased mitochondrial abundance was observed in embryonic Ahr-/- or TCDD-exposed 
Ahr+/+embryonic hearts [27]. In agreement with these findings in embryonic hearts, ventricles of 
adult Ahr+/+ females exposed in utero to high-dose TCDD showed highly significant changes in 
the expression of genes in the canonical mitochondrial pathway (Fig. 5A) and in the oxidative 
phosphorylation pathway (Fig. 5B), relative to naïve Ahr+/+ females. A small subset of changes 
was concordant between low-and high-dose TCDD. No similar findings were noted in Ahr-/- 
females or in any of the male treatment groups.  
Changes in two of the mitochondrial pathway genes, Cox14 and Mrpl12, which we found 
to be dysregulated in embryonic hearts as a result of AHR disruption [27], persisted in the adult 
hearts. Cox14 (Cytochrome C Oxidase Assembly Homolog 14), encodes a protein central to the 
synthesis and assembly of Complex IV and has been associated with mitochondrial Complex IV 
deficiency [58]. Mrpl12 (Mitochondrial Ribosomal Protein L12) encodes a nuclear-encoded 
mitochondrial ribosomal protein essential for mitochondrial protein synthesis [59] that has been 
associated with disturbed mitochondrial function and dilated cardiomyopathy [60]. In addition, 
members of the UCP uncoupling protein family were also among the dysregulated mitochondrial 
function genes. Gene expression levels of the three members, Ucp1, Ucp2, and Ucp3, were 
measured by qRT-PCR in atria and ventricles of all experimental males and females. No significant 
differences or trends were noted for Ucp1 (Fig. 6A). Ucp2 mRNA levels were significantly 
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increased in the ventricles of Ahr-/- females and in Ahr+/+females exposed to either dose of TCDD 
(Fig. 6B). Ucp3 mRNA levels were about 4- to 5-fold significantly increased in the right atrium of 
Ahr-/- and high- and low-dose TCDD-exposed Ahr+/+ males, respectively; a similar albeit not 
statistically-significant trend was noted in the left atrium of Ahr-/- and high- and low-dose TCDD-
exposed Ahr+/+ males. In the ventricles, Ucp3 mRNA levels were about 2- to 3-fold significantly 
increased in Ahr-/- and high- and low-dose TCDD-exposed Ahr+/+ males (Fig. 6C).  
Hearts from Ahr-/- and high- and low-dose TCDD-exposed Ahr+/+ mice were examined for 
quantity and quality of heart mitochondria. A relative quantification of mitochondria, as 
determined from the ratio of mtDNA to nuclear DNA, revealed that hearts from Ahr+/+ females 
exposed in utero to high-dose TCDD had a statistically significant 1.75-fold higher mitochondrial 
abundance relative to naïve Ahr+/+ females (Fig. 7A). No other comparison showed statistical 
significance, even though exposed wild-type males showed a trend of an increase over control that 
did not reach significance (Fig. 7A). Ultrastructurally, although no alterations to individual 
mitochondria morphology were noticed, the increase in relative mitochondria numbers correlated 
with a slightly higher sarcoplasm density in ventricular cardiomyocytes of Ahr+/+ females 
gestationally-exposed to high-dose TCDD (Fig. 7B).  
In sum, developmental AHR signaling disruption in vivo results in altered mitochondrial 
homeostasis as characterized by aberrant expression of genes belonging to mitochondrial function 
and oxidative phosphorylation, and correlative increase in relative and ultrastructural 




To gain further insight into the role of the Ah receptor in the potential gene-environment 
interactions underlying adult cardiovascular health, we induced AHR disruption, by genetic 
ablation or by ligand-induced down-regulation, during in utero cardiogenesis and followed the 
mice into adulthood. Consonant with the tenets of the DOHaD theory, we find that interference 
with endogenous AHR functions during embryonic development causes molecular, structural, and 
functional departures from homeostasis in the adult hearts. Some of the alterations are reminiscent 
of the alterations observed under similar conditions in the embryonic mouse heart [27]. However, 
unlike the embryonic hearts, which showed extensive similarities between Ahr genetic ablation 
and ligand-induced down-regulation, the adult hearts from the same mice showed a limited number 
of similarities and this were more evident in the female adult Ahr-/-mice than in the males. A 
summary of these observations is shown in Supplemental Table S3. 
At 10 months of age, adult Ahr-/- male and female mice had pronounced hypertrophic 
cardiomyopathy evidenced by increases in heart weight, ventricular mass myofiber cross-sectional 
area, interstitial fibrosis, and diastolic left ventricle volume. Ahr-/- males had slightly decreased 
resting heart rates. There were no significant blood pressure differences in Ahr-/- males or females. 
Even though the magnitude of change of interstitial fibrosis is not likely to be a major contributor 
to the observed increase in heart weights, it is evidence of ongoing myocardial remodeling with 
loss of contractile myofiber units and their replacement with non-contractile and non-conducting 
supporting matrix. While the heart function in Ahr-/- mice was largely compensated at resting 
conditions, as judged from the lack of correlative decreases in ejection fraction, there was a major 
effect in exercise endurance under strenuous forced running. Overall, these findings are in 
agreement with previous findings in Ahr knockout mice [30], although the progressive left 
ventricular dilation and the higher severity in Ahr-/- females in the current study have not been 
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previously reported.  Sex- and ethnicity-dependent dimorphic differences in the prevalence of 
human cardiac disease have been epidemiologically attributed to social and socio-economic 
reasons [61], and differences in the outcomes of cardiac disease complications have been reported 
[4].  
Ahr+/+ males exposed to high-dose TCDD had a milder cardiac phenotype characterized 
by slightly decreased left ventricle mass from PND 150 onwards, and decreased diastolic left 
ventricle volume at PND 270. These findings generally correlated with a larger proportion of 
cardiac myofibers having smaller cross-sectional area, corroborating that AHR disruption through 
developmental exposure to a potent ligand like TCDD results in decreased myocardial mass, as 
described previously [16,27,62]. High- and low-dose exposure to TCDD in Ahr+/+ males and 
females also yielded significantly increased systolic and mean blood pressure at PND 270, and the 
males had increased resting heart rates. AHR-mediated increases in systemic blood pressure have 
been previously documented [63], although the present study may represent the first correlation 
between in utero AHR disruption and altered blood pressure in the adult. In and of itself, chronic 
hypertension is a highly prevalent condition and one of the most powerful contributors to 
cardiovascular disease in humans [64,65].   
In spite of the absence of overt echocardiographic functional alterations, Ahr+/+ males and 
females exposed to high-dose TCDD also displayed decreased exercise endurance under strenuous 
forced running, similar to what we noted in Ahr-/- mice. Exercise endurance is a complex phenotype 
determined by the collective contributions of the central nervous system, cardiovascular and 
respiratory systems, and skeletal muscle, as well as systemic metabolism [44], where the 
cardiovascular system and energy metabolism critically contribute to positive exercise outcomes. 
Specifically, tissue perfusion, a direct consequence of preserved cardiovascular homeostasis, and 
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mitochondrial capacity are tightly correlated with positive exercise outcomes [66]. Our 
observations suggest that AHR disruption impairs exercise endurance via mechanisms that include, 
but are not limited to, the cardiovascular system and energy metabolism. A more focused analysis 
must await data from heart-specific Ahr knockout mice. In agreement with this concept, genes 
important to maintain cardiac structural homeostasis, contractility, promotion of cardiac 
hypertrophy, and regulation of cardiomyocyte energy homeostasis had significantly altered levels 
of expression in the TCDD-exposed Ahr+/+ female hearts, but not in Ahr-/- hearts or in TCDD-
exposed males. Down-regulated pathways were annotated to heart damage, function, and 
contractility, while up-regulated pathways included hypoxia signaling in the cardiovascular 
system, calcium signaling, mitochondrial dysfunction, oxidative stress response, and hormone 
nuclear receptor signaling. Upstream regulators predicted to explain these effects included critical 
players such as Hand2 and miR-155, which have been associated with congenital heart disease 
[67] and hypertrophic cardiomyopathy [46], respectively.  
Surrogate calcium-handling protein networks contributed modestly to AHR disruption-
driven alterations in myocardial structure in Ahr-/- and TCDD-exposed Ahr+/+ mice, with only 
slightly altered expression of key calcium-handling networks noted at the mRNA (decreased 
Slc8a2, Ryr2, and Pln) and protein (increased NCX) levels. Increased NCX levels have been linked 
to the genetic reprogramming that underlies cardiac remodeling and hypertrophy [68]. When 
compared to the transcriptome of embryonic hearts after AHR signaling disruption in utero [27], 
the adult transcriptome bears no striking signature of persistent genes, though expression of some 
genes, such as Col5a3, Nppa, Cox14, Mrpl12, and Wdr83, persisted in some experimental groups 
and are annotated to cardiovascular ontogenies or mitochondrial function. 
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Mitochondrial function and oxidative phosphorylation pathways were significantly down-
regulated in TCDD-exposed Ahr+/+ female but not Ahr+/+ male hearts, nor in Ahr-/- mice of either 
sex, once more illustrating a more pronounced phenotype in females. Sex-related differences have 
been observed in cardiovascular diseases in humans, and dimorphic gene expression has been 
recently observed in the expression of mitochondrial genes in young and old rats [69], although 
information regarding differential mitochondrial activity and development of cardiac diseases 
between the sexes is lacking in both humans and laboratory animals. Dimorphism is unlikely to 
result from a single unifying mechanistic model, but rather from the integration of multiple 
mechanisms involving hormonal regulation of gene expression, associated with estrogen levels 
and their indirect regulation by the AHR. 
 Two members of the mitochondrial uncoupling family (UCP), Ucp2 and Ucp3, were up-
regulated in one or more heart compartments of Ahr-/- and high- and low-dose TCDD-exposed 
Ahr+/+ mice, which suggests a compensatory response, as UCP2 is typically decreased in 
expression in the failing heart [70]. These findings are in line with previous studies showing that 
AHR disruption is associated with mitochondrial dysfunction [27,50] and with UCP dysregulation 
[71]. The observed molecular alterations to mitochondrial function and oxidative phosphorylation 
were accompanied by a slight increase in mitochondria abundance, similar to previous 
observations in embryos [27], limited to high-dose TCDD-exposed Ahr+/+ female hearts and 
without accompanying mitochondrial ultrastructural abnormalities.  
6. Conclusions 
The immediate effects triggered in the embryo by the disruption of endogenous AHR 
functions do not seem to subside with age but rather diverge and diversify into multiple directions 
encompassing pathways controlling cardiomyocyte structure and function, including hypertrophy 
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signaling and mitochondrial function, ultimately resulting in compensated adult cardiomyopathy. 
Multiple interconnected compensatory responses are likely at play in the adult heart to cope with 
the developmental setbacks resulting from AHR-disruption. Seemingly, constitutive ablation of 
the AHR yields sustained and more complex molecular departures from homeostasis, relative to 
pharmacological disruption of the receptor, which ultimately translates into a more severe adult 
phenotype. In addition, maternal cardiovascular dysfunction and abnormal placental development 
may contribute to the more pronounced phenotype in Ahr-/- mice. Interestingly, across all endpoints 
evaluated, a majority of the findings driven by AHR disruption described in this study are generally 
more pronounced in females than in males, underscoring the sexual dimorphism of the phenotypes. 
Unlike in the embryonic heart, where AHR ablation and dowregulation by ligand appear to follow 
parallel pathways, these two conditions are substantially more divergent in the adult heart. While 
no overt cardiac insufficiency was observed at 10 months of age, our findings suggest that the 
compensatory mechanisms at play may be insufficient to cope with added environmental stressors. 
Our findings extend our understanding of the central role of the AHR signaling network in 
cardiovascular function and dysfunction, which makes it an important gene-environment nexus in 
environmental cardiac injury.   
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Figure 1. In utero disruption of AHR signaling affects adult cardiovascular function. Naïve 
Ahr+/+ and Ahr-/- and high- and low-dose TCDD-exposed Ahr+/+ mice were assessed for 
cardiovascular function on postnatal days (PND) 60, 90, 150, and 270. Absolute left ventricle mass 
(A), normalized left ventricle mass (B), left ventricle volume (C), and ejection fraction (D) were 
derived from echocardiographic examination of heart function. Conscious heart rate (F) and 
systolic blood pressure (G) were determined by the tail-cuff method on PND 270. Exercise 
endurance was assessed by forced treadmill exercise on PND 60, 90, 150, and 270. All data is 





Figure 2. In utero disruption of AHR signaling affects adult heart structure and transcriptome. 
(A) Heart weights (normalized to body weight) at necropsy (PND 300) from naïve Ahr+/+ and Ahr-
/- and high- and low-dose AHR ligand-exposed Ahr+/+ mice. Wheat germ agglutinin (B) staining 
of 5-µm-thick sections were used to highlight the cross-sectional myofiber profiles which were 
used to ascertain the myofiber cross-sectional area (C), which are expressed as means ± minimal 
and maximal measured areas. Nuclei are stained in blue by DAPI-counterstain; 40X objective. 
Masson’s trichrome staining (D) was used to highlight the myocardial extracellular matrix as a 
proxy for fibrosis (E); 40X objective. (F) Number of differentially expressed genes in the adult 
heart as a consequence of AHR disruption in utero, from Ahr-/- and TCDD-exposed Ahr+/+ right 
atrium (RA), left atrium (LA), and ventricle (V) tissue from males and females. (G) Compartment-
specific number of persistent genes (i.e., differentially expressed in the embryonic heart and in the 




Figure 3. Differentially expressed canonical pathways, toxicological functions, and upstream 
regulators underlie AHR disruption-driven altered cardiac structure and function. (A) Fold 
change expression of differentially expressed Ingenuity Pathway Analysis (IPA) canonical 
pathways and toxicological functions from and Ahr-/- females and high- and low-dose TCDD-
exposed Ahr+/+ females relative to naïve Ahr+/+ males. (B) IPA’s upstream regulators from Ahr-/- 






Figure 4. In utero disruption of AHR signaling modestly affects calcium-handling signaling in 
heart. Fold change mRNA expression of Nkx2-5 (A), Slc8a2 (B), Ryr2 (C), and Pln (D), and 
protein expression of NCX (E) from naïve Ahr+/+ and Ahr-/- and high- and low-dose TCDD-




Figure 5. Mitochondrial dysfunction and altered oxidative phosphorylation genes in the adult 
heart as a result of in utero disruption of AHR signaling. Fold change of expression of 
significantly altered genes in (A) functional mitochondrial pathways and (B) oxidative 




Figure 6. Uncoupling proteins are differentially expressed following in utero disruption of AHR 
signaling. Fold change of expression of Ucp1 (A), Ucp2 (B), and Ucp3 (C) at PND 300 of naïve 
Ahr+/+ and Ahr-/- and high- and low-dose TCDD-exposed Ahr+/+ mice. All data is expressed as 




Figure 7. Disruption of AHR signaling induces changes in cardiac mitochondria abundance 
and structure - (A) Quantification of heart mitochondrial DNA (mtDNA) relative to nuclear DNA 
(nDNA), defined as the ratio of mtDNA to nDNA ratio at PND 300 and expressed as the mean 
fold change relative to naïve Ahr+/+ hearts ± SEM; * p≤0.05. All data is expressed as mean ± SEM 
where *p< 0.05. (B) Ultra-thin sections of embryonic hearts collected at PND 300 from Ahr-/- and 
Ahr+/+, either naïve or exposed to high- or low-dose ligand in utero, were used for transmission 
electron microscopy evaluation of the embryonic heart ultrastructure. Illustrative 
photomicrographs showing the density of mitochondria (arrowheads) within the cardiomyocyte 
sarcoplasm in Ahr-/- and in high- and low-dose TCDD-exposed Ahr+/+ mice compared to naïve 
Ahr+/+ mice. Uranyl acetate and lead citrate stain. Scale bar = 2 µm.   
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1. Supplemental Materials and Methods  
a. Animals and Treatments 
All experiments were conducted using the highest standards of humane care in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals and were approved in advance 
by the University of Cincinnati Institutional Animal Care and Use Committee. C57BL/6J mice 
used in these experiments were originally purchased from The Jackson Laboratory and thereafter 
maintained in our colony. C57BL/6J mice were housed in a pathogen-free animal facility under a 
standard 12-hour light/12-hour dark cycle with ad libitum water and chow. Ahr-/-mice crossed for 
7 generations into a C57BL/6J background were initially purchased from Jackson labs and 
thereafter maintained to date in our laboratory into the C57BL/6J genetic background (for about 
14 years). On gestation day (GD) 7.5, pregnant Ahr+/+ dams were treated by oral gavage with either 
corn oil (vehicle) or with TCDD (0.1 or 1 μg/kg of maternal weight) in corn oil vehicle, which was 
repeated on embryo days E9.5 and E11.5; Ahr-/- pregnant dams remained untreated throughout 
gestation.  
b. RNA.seq analysis 
Following euthanasia, hearts were immediately harvested and rinsed with RNA-Later 
(Ambion). Each heart was microdissected into right atrium, left atrium, and ventricles. Individual 
samples were stored in 200 µL of RNA-Later at -80°C until RNA extraction. Total RNA was 
extracted with the RNeasy Mini Kit with Proteinase K and DNAse steps (QIAGEN) according to 
the manufacturer’s instructions.  
All steps of library construction, cluster generation, and HiSeq (Illumina) sequencing were 
performed with triplicate samples by the Genomics Sequencing Core of the Department of 
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Environmental Health, University of Cincinnati. Library construction was done with the TruSeq 
RNA sample preparation kit (Illumina) using 1 μg of total RNA, with RNA integrity number ≥ 7.0 
as determined with an Agilent 2100 Bioanalyzer (Agilent Technologies) to purify poly-A–
containing mRNA with oligo-dT–attached magnetic beads. The purified mRNA was 
enzymatically fragmented, with random hexamers primed for first and second strand cDNA 
synthesis, followed by purification using Agencourt AMPure XP beads (Beckman Coulter). 
Overhangs in the double-strand cDNA were blunt-ended by end repair and adenylated with a single 
A-nucleotide at the 3´ end to prevent self-ligation in the following ligation step. AMPure XP bead-
purified fragments were ligated to sample-specific indexing adapters and enriched by 10 cycles of 
PCR using adapter-specific primers. A 1-μL aliquot of purified PCR product (from a total 
sequencing library of 30 μL) was analyzed in an Agilent bioanalyzer using a DNA 1000 chip to 
check DNA size (~ 260 bp) and yield. To quantify the library concentration for clustering, the 
library was diluted 1:100 in a buffer containing 10 mM Tris-HCl, pH 8.0, and 0.05% Tween 20, 
and analyzed by quantitative PCR (qPCR) with a KAPA Library Quantification kit 
(KapaBiosystems) using an ABI 9700HT real-time PCR machine (Applied Biosystems). Equal 
amounts of six individually indexed cDNA libraries were pooled for clustering in an Illumina cBot 
system flow cell at a concentration of 8 pM using Illumina’s TruSeq SR Cluster Kit v3, and 
sequenced for 50 cycles using a TruSeq SBS kit on the Illumina HiSeq system. Each sample 
generated approximately 30 million sequence reads. Sequence reads were demultiplexed and 
exported to fastq files using CASAVA 1.8 software (Illumina). The reads were then aligned to the 
reference genome (mm10) using TopHat aligner. The counts of reads aligning to each gene’s 
coding region were summarized using ShortRead and associated Bioconductor packages 
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(GenomicFeatures, IRanges, GenomicRanges, Biostrings, Rsamtools) for manipulating and 
analysis of next-generation sequencing data and custom-written R programs. 
Differential gene expression analyses between Ahr+/+ and Ahr-/- hearts or between AHR 
ligand-exposed Ahr+/+ and naïve Ahr+/+ hearts were performed separately. Statistical analyses using 
the negative-binomial model of read counts as implemented in the Bioconductor DESeq package 
were performed to identify differentially expressed genes for each comparison. Significant genes 
were selected based on a false-discovery rate–adjusted p-value < 0.0001. RNA.seq data was further 




2. Supplemental Figures  
 
k. Supplemental Figure S1 - (A) Experimental design for gestational exposure to the 
prototypical AHR ligand (TCDD). (B) Body weight (grams) from naïve Ahr+/+, low- and high-
dose ligand-exposed Ahr+/+, and Ahr-/- males and females at the indicated age (in days). Mean 
± SEM. (C) Echocardiographic assessment of aorta diameter (µm) from naïve Ahr+/+, ligand-
exposed Ahr+/+, and Ahr-/- males and females at the indicated age (in days). Mean ± SEM; * 
p≤0.05. (D) Mean blood pressure (mmHg) from naïve Ahr+/+, ligand-exposed Ahr+/+, and Ahr-
/- males and females at 9 months (postnatal day [PND] 270). Mean ± SEM; * p≤0.05. (E) 
RNA.seq data analysis design for adult heart transcriptome at PND 300 and comparison 




3. Supplemental Tables 
 
a. Supplemental Table S1- Identity of genes differentially expressed in the embryo at E13.5, 
E15.5, or E18.5 and which persisted in the adult hearts at postnatal day (PND) 300. 
 
Naïve Ahr-/- Ahr+/+ High TCDD  Ahr+/+ Low TCDD  
Males Females Males Females Males Females
Right Atrium
























b. Supplemental Table S2- Identity, function, targets, and fate of selected cardiovascular 
signaling pathways genes and proteins in cardiac hypertrophy and failure adapted from 
McLennan et al [48]. 
  
Selected Cardiovascular Signaling Pathways 
Gene Protein Function Target Hypertrophy Failure
Atp2a1, Atp2a2 SERCA Ca from cytosol to lumen of SER PLN ↑ or ↓ ↓ 
Slc8a2, Slc8a3, Slc8a4 NCX Na/Ca exchanger, Ca out of cell Ca/Na ↑ or ↓ ↑ 
Ryr2 RyR Ca-mediated Ca release into cytosol Junctin
↑ or ↓
Or no change No change
S2808 p-RyR2 RyR No change ↑ (arrythmogenic)
S2814 p-RyR3 RyR No change ↑ (arrythmogenic)
Pln PLN Inhibits SERCA SERCA No change/down No change
T17 p-PLN SERCA ↑ or ↓ ↓
S16 p-PLN SERCA ↑ or ↓ ↓




Sex Male Female 
Ahr Disruption Condition Ahr-/- TCDD Ahr-/- TCDD 
Molecular Findings  
(affected networks) 
Congenital Heart Anomaly - - -  
Cardiac Homeostasis -    
Cardiac Stress - - -  
Mitochondrial Dysfunction     
Energy Metabolism - - -  
Heart Structure Heart Weight  -   
LV Mass  or -  or -  - 
LV Volume   or -  - 
Myofiber Size -   - 
Fibrosis     
Heart Function Heart Rate -   - 
Blood  Pressure -  -  
Endurance     or - 
Mitochondria Oxidative Phosphorylation - - -  
Mitochondrial Abundance - - -  
 
c. Supplemental Table S3: Summary of cardiovascular findings related to developmental Ahr 
disruption in male and female mice. Arrow up = upregulated/increased, arrow down = 










1. Conclusions and Implications  
The focus of this dissertation is the characterization of the embryonic and adult effects of 
developmental (in utero) aryl hydrocarbon receptor (AHR) disruption, primarily regarding the role 
of this protein in cardiogenesis in the embryo, and cardiac homeostasis function in the embryo and 
adult.  
Congenital heart disease (CHD) is the potential adverse outcome of perturbing 
cardiogenesis, and is the most common birth defect and a leading cause of neonatal and adult 
cardiac disease in humans. The majority of patients born with CHD lack an etiological diagnosis; 
as such, efforts towards prevention of CHD are currently a challenge. Furthermore, 
notwithstanding a wealth of scientific effort, the overall pathogenesis of CHD remains elusive. In 
this context, gene-gene and gene-environment interactions have been investigated as key 
contributors to congenital heart disease.  
Epidemiological studies have linked specific environmental factors with increased risk for 
development of CHD. Specifically, exposures to environmental pollutants which are known 
ligands of the AHR have been implicated in increased risk of CHD and overall cardiovascular 
disease in humans [71-73]. Accordingly, in agreement with the tenets of the Developmental 
Origins of Health and Disease (DOHaD) theory [16-18], it has been previously suggested that in 
utero exposure to exogenous AHR ligands affects the postnatal heart [41].  
Consistent with the hypothesis that the AHR participates in cardiac formation and function, 
it has been shown that knockout of the Ahr gene in mice disrupts cardiovascular homeostasis, 
causing pathological cardiac hypertrophy [83]. While previous studies have alluded to a potential 
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direct role of the receptor in cardiogenesis and function, detailed characterizations of the overall 
consequences of perturbing the endogenous expression of the Ahr were wanting.  
Across the body of this current work, we illustrate that interference with endogenous AHR  
functions  during early development (in vivo), through either gene ablation or exposure to TCDD, 
perturbs cardiogenesis and leads to molecular and structural cardiac abnormalities. These effects 
culminate in departure from functional homeostasis in the embryo which persists, and for some 
parameters progresses, in adulthood.  
By targeting the post-implantation period of organogenesis, a critical window of 
susceptibility for the cardiovascular system, we developed a gestational exposure model which 
enabled us to assess the consequences of AHR disruption to the cardiogenesis program while 
providing the means to characterize the role of the AHR in gene-environment interactions during 
mouse cardiogenesis.  
In agreement with previous evidence generated in the Puga Lab at the University of 
Cincinnati and at other laboratories, the findings described herein confirm that the AHR/TCDD 
axis has an important role in the development of the heart. Specifically, disruption of endogenous 
AHR functions in utero and the resulting altered ventricular composition and decreased ventricle 
thickness and mass in the mouse embryo that correlates with echocardiographic alterations of fetal 
and adult heart function. In addition, some of the molecular and structural alterations in the adult 
mice are reminiscent of the alterations observed under similar conditions in the embryonic mouse 
heart. 
TCDD in utero-exposed adult Ahr+/+ mice develop significantly increased systolic and 
mean blood pressures, and the males also have increased resting heart rates. While the AHR has 
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been previously shown to mediate increases in systemic blood pressure [99], our data appears to 
represent the first correlation between in utero AHR disruption and altered blood pressure in the 
adult. This finding alone underscores the potential for genetic and environmental contributions to 
adult disease, considering that chronic high blood pressure is a highly prevalent and the most 
powerful contributor to cardiovascular disease in humans [100,101].  
Ultimately, in utero AHR disruption, be it from genetic ablation or agonist exposure, also 
results in decreased exercise endurance in adults under strenuous forced running, even though only 
Ahr-/- adult mice develop pathological and echocardiographic findings consistent with pronounced 
hypertrophic cardiomyopathy. This distinction suggests that impaired exercise endurance in adults 
exposed to TCDD in utero may be the net result of effects beyond the heart and circulatory system, 
potentially having to do with more general dysfunction of metabolism and energy handling in the 
liver and skeletal muscles. 
AHR disruption also results in molecular dysregulation of mitochondrial function, 
increased mitochondrial abundance and, in embryos only, ultrastructural alterations suggestive of 
mitochondrial stress and degeneration in the heart. Developmental AHR signaling disruption in 
vivo results in aberrant cardiac expression of genes belonging to mitochondrial function, TCA 
cycle, and oxidative phosphorylation. The developing and adult hearts have critically high demand 
for energy such that these mitochondrial molecular and structural observations are expected to be 
contributory to the observed impaired cardiovascular functional outcomes. Furthermore, altering 
mitochondrial homeostasis may have direct consequences to increased reactive oxygen species 
production, calcium handling, and apoptosis regulation, all of which have the potential to cause 
cardiomyocyte degeneration and death. We specifically investigated the contributions of key 
calcium-handling proteins, such as phospholamban, ryanodine receptor, sodium-calcium 
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exchanger, and SERCA, and found that canonical calcium-handling mechanisms in the adult heart 
are preserved following AHR disruption in utero. Therefore, altered calcium handling does not 
seem to be a major contributor to the altered myocardial structure driven by AHR activation or 
loss-of-function. 
While studying the mechanisms underlying the molecular, structural, and functional 
phenotypes, we found altered AHR endogenous expression in the mouse fetal heart as early as 
embryonic day (E) 13.5, with a nuclear localization pattern even in the absence of an exogenous 
ligand. Critically, exogenous ligand-mediated activation decreases the overall nuclear localization 
of the AHR, alluding to a potential misappropriation from its endogenous function at this critical 
cardiogenesis developmental time. Concomitantly, the master cardiogenesis transcription factor 
Nkx2.5 is repressed, resulting in the dysregulation of genes controlling pathways responsible for 
attainment and maintenance of cardiac differentiation, homeostasis, and function.  
In utero AHR disruption derails key cardiogenesis programs which subsequently 
dysregulate entire networks generally pertaining to hypoxia and calcium signaling, mitochondrial 
dysfunction, energy metabolism, oxidative stress response, and hormone nuclear receptor 
signaling in both embryos and adult hearts. In addition, selected genes annotated to cardiovascular 
ontogenies or mitochondrial function persist (i.e., differentially expressed in the embryonic and 
also in the adult heart) and may represent central mechanisms of the observed toxicity. Seemingly, 
disruption of AHR signaling during development yields lasting effects in the adult heart 
transcriptome, chiefly on networks related to cardiovascular homeostasis and function, with 
quantitative and qualitative differences between the atria and ventricles and with a predominance 
of effects in the adult female heart.   
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In the embryo cohort, a striking degree of similarity in the identity and direction of change 
was noted between differentially expressed genes in Ahr-/- and TCDD-exposed Ahr+/+ mice. This 
pattern is in agreement with previous observations that proteasome-dependent degradation of 
ligand-activated Ah receptor may transiently decrease the overall cellular amount of receptor and 
result in “post-exposure AHR down-regulation”  [25-26, 19]. In contrast, in the adult cohort there 
are appreciable differences at the transcriptional and phenotypic levels between Ahr-/- and TCDD-
exposed Ahr+/+ mice at most endpoints evaluated, illustrating that the sustained nature of the 
transcriptome deregulation in Ahr-/- fans-out into distinct outcomes to the cardiovascular system.  
Lastly, one curious aspect about the adult cohort studies is the observation of sexually 
dimorphic cardiac phenotypes. Gender-biased differences have been observed in cardiovascular 
diseases in humans [3], although a deeper mechanistic understanding of differential development 
of cardiac diseases between the sexes is lacking in both humans and laboratory animals. A logical 
candidate to potentially explain sexually dimorphic responses is the endocrine system, particularly 
with respect to sex hormone (such as estrogen and estrogen receptor) signaling. In the context of 
our studies, ligand-activated AHR has been shown to inhibit estrogen receptor signaling via 
different mechanisms [103-104], and the Ahr-/- female mouse displays impaired reproductive 
outcome [81].  These prior findings suggest that estrogen signaling may be a key player in the 
observed female-biased phenotypes of developmental AHR disruption, a possibility supported by 
the higher expression of cardiac structural and functional abnormalities in adult females exposed 




2. Future Directions 
The results outlined in this dissertation provide strong evidence in support of a central role 
for the AHR signaling network in heart development, where the AHR is also a target of 
environmental agents that can cause departure from homeostasis and thereby underlie congenital 
heart disease. One critical aspect of our findings is that they take place at TCDD doses well below 
the well-characterized teratogenic doses that cause cleft palate and hydronephrosis in mice, 
underscoring the relevance of our findings to environmental health. Considering the present burden 
and social-economic impact of cardiovascular diseases in the young and adult human populations, 
understanding which and how the environmental insults during fetal life, such as the ones mediated 
by AHR/TCDD axis, result in congenital and postnatal cardiac disease is crucial to the 
understanding of the etiology for the vast majority (over 4 in 5) of CHD cases. The findings from 
this study are aligned to advance our mechanistic understanding of cardiac developmental 
dysfunction and improve our ability to prevent environmentally-induced cardiac injury.  
Future direction for this work include a more focused analysis of heart-specific Ahr 
knockout mice, to ascertain which of the observed effects is dependent on cardiomyocyte-specific 
AHR, as well as advancing the developmental AHR disruption model by exposing mice of at-risk 
genotypes, such as the haploinsufficient Nkx2.5+/Cre mice. Further investigating the interplay 
between AHR and NKX2-5 signaling networks is a promising lead in advancing our understanding 
of AHR-mediated developmental cardiotoxicity. In addition, the sexually-dimorphic presentation 
of some of the AHR ligand-induced adult phenotypes, favoring females, can be further explored 
with study cohorts specifically powered to confirm and scrutinize these sex-biased responses. 
Exploring the mechanisms underlying the differences between developmental AHR disruption in 
male and female embryos may further expand our understanding of AHR physiology. Our adult 
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cohort studies suggest that in utero exposure to TCDD may also affect metabolism and energy 
handling mechanisms in tissues beyond the heart, such as in the liver and skeletal muscles. As 
such, further investigating this lead may provide critical insights in the developmental origins of 
adult metabolic disease, with critical implications in highly prevalent diseases such as diabetes and 
obesity.     
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